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ABSTRACT	
The	 number	 of	 newly	 engineered	 nanomaterials	 is	 vastly	 increasing	 and	 so	 are	 their	
applications.	Even	though	a	lot	of	interest	and	effort	are	being	put	into	the	development	of	
nano‐based	biomedical	applications,	the	level	of	translational	clinical	output	remains	limited	
due	 to	 uncertainty	 on	 the	 toxicological	 profiles	 of	 the	 nanoparticles	 (NP).	 As	NP	 used	 in	
biomedicines	are	 likely	to	directly	 interact	with	cells	and	biomolecules,	 it	 is	 imperative	to	
rule	 out	 any	 adverse	 effect	 before	 they	 can	 be	 safely	 applied.	 Nanotoxicity	 is	 preferably	
evaluated	in	vitro,	but	extrapolating	the	obtained	data	to	a	realistic	in	vivo	scenario	remains	
challenging.		In	addition,	generated	data	are	often	conflicting,	which	consolidates	the	in	vitro‐
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in	 vivo	 gap	 and	 impedes	 the	 formulation	 of	 unambiguous	 conclusions	 on	 NP	 toxicity.	 To	
bridge	this	gap,	more	consistent	and	relevant	in	vitro	and	in	vivo	data	need	to	be	acquired,	
which	is	in	conflict	with	the	incentive	to	reduce	the	number	of	animals	used	for	in	vivo	toxicity	
testing.	Therefore	the	need	for	more	reliable	in	vitro	models	with	a	higher	predictive	power,	
mimicking	the	in	vivo	environment	more	closely,	becomes	more	prominent.	In	this	review	we	
will	discuss	the	current	paradigm	for	nanotoxicity	evaluation	and	summarize	the	principles	
of	current	routine	methods	 for	nanotoxicity	assessment.	We	will	also	give	an	overview	of	
adjustments	that	can	be	made	to	the	cultivation	systems	to	optimise	current	in	vitro	models,	
thereby	bridging	the	in	vitro‐in	vivo	gap	as	well	as	describe	various	novel	model	systems	and	
highlight	future	prospects.	
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1. Introduction	
Since	the	1980’s	the	field	of	nanotechnology	has	increasingly	gained	importance,	leading	to	
a	boom	in	applications	since	the	1990’s.	In	our	current	society,	inorganic	nanoparticles	(NP)	
are	being	applied	in	many	different	ways.	ZnONP,	for	example,	are	used	in	sunscreens	and	
toothpastes	 and	 AgNP	 can	 be	 found	 in	 food	 packages,	 deodorants	 and	 are	 applied	 as	 a	
preservative	in	cosmetics	1‐3.		
Given	 the	ever	 increasing	use	of	NP	 in	 technological	applications	and	everyday	consumer	
goods	and	the	high	 interest	of	exploiting	 the	exceptional	 features	of	 the	NP	 in	biomedical	
applications,	 it	 is	 expected	 that	 both	 intentional	 and	 unintentional	 exposure	will	 become	
more	 frequent	 4,	5.	Because	of	 this,	 the	 increase	 in	nanotechnology	 implementation	 in	our	
daily	lives	is	joined	with	the	raising	of	concerns	on	potential	adverse	effects	towards	human	
health	6.	It	is	therefore	recommended	that	the	safety	of	these	products,	towards	consumers	
and	 especially	 towards	 workers	 at	 the	 production	 site,	 is	 carefully	 evaluated	 before	 its	
introduction	to	the	market	4,	5,	7.	However,	there	are	currently	only	very	limited	regulations	
on	the	use	and	the	safety	criteria	for	nanomaterials	in	industrial	applications	or	consumer	
goods.	Major	obstacles	on	 the	 route	 to	an	appropriate	 legislation	are	 the	broad	nature	of	
nanotechnology,	the	incredible	pace	at	which	the	field	keeps	advancing	and	the	enormous	
variety	 in	 types	 of	 nanomaterials,	 each	 with	 different	 physicochemical	 properties	 and	
specific	applications	7.	An	appropriate	legislation	should	cover	all	aspects	of	nanotechnology	
without	any	material	or	application	being	left	out,	which	from	a	practical	point	of	view,	 is	
extremely	 hard	 to	 obtain.	 In	 order	 to	 try	 and	 overcome	 this	 predicament,	 the	 European	
Commission	launched	a	recommendation	on	a	definition	of	nanomaterials	in	2011	that	states	
that	a	nanomaterial	is:	“A	naturel,	incidental	or	manufactured	material	containing	particles,	
in	an	unbound	state	or	as	an	aggregate	or	as	an	agglomerate	and	where,	for	50%	or	more	of	
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the	particles	in	the	number	size	distribution,	one	or	more	external	dimensions	is	in	the	size	
range	 from	1	 ‐	100	nm	8.”	As	every	definition	has	 its	 limitations	and	 introduces	 technical	
challenges,	 regulatory	 bodies	 have	 not	 yet	 come	 to	 a	 global	 agreement	 of	 the	 correct	
definition,	but	the	most	used	criterion	is	the	size	limitation	9‐11.		Nanotechnology	itself	can	
subsequently	be	described	as	the	manipulation	and	application	of	particles	and	systems	with	
at	least	one	dimension	below	100	nm	10.	For	nanomedicine	purposes	these	technologies	are	
being	 used	 to	 develop	 applications	 for	 diagnosis	 12,	 13,	 imaging	 14,	 15,	 treatment	 16,	 17	 and	
prevention	of	diseases	18‐20.	One	of	the	latest	developments	in	nanomedicine	are	theranostic	
particles,	which	combine	imaging	or	diagnostic	and	therapeutic	features	in	a	single	construct	
21,	22.	Wang	et	al.	 for	example,	developed	magnetic	micelles	for	gene	delivery,	enabling	the	
monitoring	 of	 the	 delivery	 efficiency	 after	 administration	 and	 Kirui	 et	 al.	 created	 an	
immunotargeted	 gold‐coated	 iron	 oxide	 NP	 (IONP)	 to	 visualise	 colorectal	 tumours	 by	
magnetic	resonance	imaging	followed	by	treatment	with	hyperthermia	23,24.						
It	is	due	to	the	minute	dimensions	of	the	NP	that	they	exhibit	many	unique	properties	(e.g.	
IONP	are	superparamagnetic	 25	and	AuNP	have	a	 localised	surface	plasmon	resonance	 26)	
because	 of	 which	 they	 can	 be	 implemented	 in	 novel	 innovative	 applications	 27.	 These	
dimensions	are	on	the	other	hand	also	often	the	cause	of	adverse	health	effects	through	the	
higher	surface	to	volume	ratio	and	enhanced	surface	reactivity	28,	29.	The	fact	that	both	the	
great	potential	and	the	high	risk	lie	in	the	miniature	dimensions	of	the	materials	is	refered	to	
as	 the	nanomaterial‐paradox	and	underscores	 the	 importance	of	 a	 thorough	 toxicological	
analysis	9.	Even	though	nanotechnology	has	been	evolving	since	the	1980’s,	 it	was	only	in	
2004	that	Donaldson	et	al.	mentioned	the	importance	of	nanotoxicology	‐	as	a	subcategory	of	
toxicology	 ‐	 to	enable	 the	 further	development	of	safe	and	sustainable	nanotechnology	30.	
Nanotoxicology	itself	refers	to	the	study	on	interactions	between	NP	and	biological	systems	
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with	 an	 emphasis	 on	 establishing	 a	 relationship,	 if	 any,	 between	 the	 physicochemical	
properties	of	the	NP	and	the	toxicological	responses	31.	It	is	crucial	to	view	nanotoxicology	as	
a	distinct	 category	of	 toxicology	 since	 it	 has	been	observed	 that	 standard	 toxicity	 assays,	
which	 were	 initially	 developed	 for	 the	 evaluation	 of	 pharmacological	 agents,	 are	 often	
inadequate	for	nanotoxicity	assessment.	This	can	be	attributed	to	the	different	mechanisms	
through	which	NP	may	evoke	toxic	effects,	the	specific	behaviour	of	the	NP	in	culture	media	
and	the	possible	 interference	of	NP	with	various	 in	vitro	and	 in	vivo	 toxicity	assays	9,	32‐34.	
Therefore	 the	classic	 toxicity‐testing	paradigm	needs	 to	be	optimised	 to	be	applicable	 for	
nanosafety	 evaluation.	 Not	 only	 the	 assays	 but	 also	 the	 cultivation	 systems	 have	 to	 be	
optimised,	as	it	has	been	shown	in	literature	that	the	experimental	design	has	the	potential	
to	influence	the	uptake	and/or	the	observed	toxicological	effects	especially	since	many	NP	
tend	to	agglomerate	and	sediment	on	top	of	cells	cultured	in	classical	2D	cultures	35‐38.	This	
review	provides	an	overview	of	current	methods	used	for	nanotoxicity	evaluation	and	factors	
related	to	the	cultivation	system	that	are	likely	to	influence	the	outcome	of	the	experiments.	
Furthermore	we	will	 propose	 adjustments	 that	 can	 be	made	 to	 the	 cultivation	 system	 to	
optimise	the	current	in	vitro	models	in	order	to	minimize	artefacts	and	more	closely	resemble	
the	 in	 vivo	 situation,	 thereby	 bridging	 the	 in	 vitro‐in	 vivo	 gap.	 These	 propositions	will	 be	
illustrated	with	recent	findings	from	literature.	
	
2. Nanotoxicology	
2.1.	Common	mechanisms	causing	nanotoxicity		
As	mentioned	above,	the	field	of	nanotoxicology	is	a	specific	subcategory	of	toxicology.	This	
subdivision	 is	 an	 absolute	 necessity,	 as	 general	 toxicology	 paradigms	 cannot	 completely	
cover	the	toxicity	induced	by	NP	30.	Generally	higher	levels	of	toxicity	are	observed	for	NP	in	
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comparison	to	the	bulk	material,	which	can	be	attributed	to	their	minute	dimensions,	as	they	
can	reach	intracellular	compartments	and	show	altered	in	vivo	biodistribution	patterns	20,	31.	
Important	 factors	 in	 this	 respect	 are	 the	 higher	 surface	 to	 volume	 ratio,	 higher	 surface	
reactivity	and	susceptibility	 to	degradation	and	 ionleaching	28,	39.	Furthermore	NP	tend	to	
behave	 differently	 in	 dispersion	 in	 comparison	 to	 chemicals	 as	 some	 are	 prone	 to	
degradation,	 agglomeration	or	aggregation	and	sedimentation,	 influencing	NP	uptake	and	
subsequently	NP	 toxicity	 35,	 40,	 41.	 Since	 these	 effects,	 as	well	 as	 other	 adverse	 effects,	 are	
highly	dependent	on	the	physicochemical	properties	of	the	NP	a	thorough	characterisation	
in	 both	 the	 dry	 state	 and	 in	 suspension	 is	 an	 absolute	 necessity	 to	 interpret	 results	 and	
formulate	 conclusions	 on	 the	 correlations	 between	 the	NP’s	 properties	 and	 the	 observed	
effects	29,	42.	From	these	issues	it	can	be	deducted	that	nanotoxicity	assessment	can	often	be	
more	complex	than	toxicity	testing	of	chemical	substances.	It	is	known	that	most	chemicals	
induce	 toxicological	 responses	 through	 interaction	 with	 specific	 biomolecules	 whereas	 a	
single	 type	 of	 NP	may	 cause	 toxicity	 via	 a	 combination	 of	 different	mechanisms	 like	 the	
induction	of	 reactive	oxygen	species	 (ROS),	genotoxicity,	morphological	modifications,	NP	
degradation	and	immunological	effects	31,	40,	43.	
Nel	 et	al.	 have	 put	 ROS	 induction	 forth	 as	 one	 of	 the	main	 common	 effects	 following	NP	
exposure	 and	 therefore	one	of	 the	main	mechanisms	 through	which	 inorganic	NP	 induce	
toxicity	as	it	has	been	observed	in	a	multitude	of	in	vivo	and	in	vitro	studies	44‐48.	For	instance,	
Wang	 et	al.	 observed	 a	 significant	 decrease	 in	 GSH/GSSH	 ratio	 in	 the	 olfactory	 bulb	 and	
hippocampus	in	mice	after	intranasal	exposure	to	IONP	49.	Soenen	et	al.	obtained	comparable	
results	 in	 an	 in	 vitro	 setting	 where	 C17.2	 neuronal	 progenitor	 cells	 showed	 a	 highly	
significant	 increase	 in	ROS	levels	after	4	or	24h	IONP	exposure	50.	ROS	can	be	 induced	by	
several	mechanisms,	including	(i)	the	interfernce	with	redox	active	proteins,	(ii	)	interaction	
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with	oxidative	organelles	such	as	the	mitochondria,	(iii)	chemical	reactions	of	the	coating,	
reactive	 surface	groups	or	 ions	 leached	 from	 the	NP	surface	 in	 the	acidic	environment	of	
endo‐	or	lysosomes	and	(iv)	by	activation	of	several	signalling	pathways	through	interaction	
with	cell	surface	receptors	28,	40.	This	paradigm	does	however	not	account	for	all	NP:	CeO2NP,	
for	 example,	were	 found	 not	 to	 cause	ROS	 induction	 but	 on	 the	 contrary	 even	 showed	 a	
protective	effect	against	ROS	damage	in	vivo	as	well	as	in	vitro	51,	52.	Furthermore,	Gao	et	al.	
observed	an	intrinsic	peroxidase‐like	activity	for	unimpaired	IONP	in	a	cell	free	environment	
and	Huang	et	al.	saw	the	same	effect	in	mesenchymal	stem	cells,	,	where	IONPs	were	found	
to	 promote	 cell	 proliferation	 53,	 54.	 Unlike	 for	 ROS	 induction	 the	 mechanism	 behind	 this	
protective	effect	has	not	yet	been	unravelled.	But	these	data	underscore	the	complexity	of	
nanotoxicology	and	the	importance	of	a	obtaining	a	toxicological	profile	that	covers	as	many	
facets	as	possible.		
Persistent	 ROS	 induction	 at	 high	 levels,	 leading	 to	 oxidative	 stress,	 can	 have	 very	 grave	
consequences	as	it	can	cause	many	secondary	effects	like	protein	denaturation,	modulation	
of	specific	signal	transduction	pathways,	inflammation,	(mitochondrial)	membrane	damage	
and	DNA	damage	28,	55.	The	ability	of	NP	to	induce	DNA	damage	through	ROS	is	however	not	
the	 only	 route	 to	 genotoxicity	 as	 it	 is	 known	 that	 NP	 can	 also	 alter	 gene	 expression	 via	
interactions	with	signal	transduction	pathways	or	with	the	transcriptional	and	translational	
machinery	 through	perinuclear	 localisation	of	 the	NP	 56,	 57.	 	 Finally,	 very	 small	NP	with	 a	
diameter	below	5	nm	may	directly	interact	with	DNA	resulting	in	DNA	damage	58.	ROS	can	
furthermore	 cause	 actin	 stress	 fibre	 formation	 and	 therefore	 alter	 the	 cell’s	morphology,	
motility	 and	 adhesion	 59,	 60.	 In	 turn	 can	 morphological	 changes	 cause	 mitochondrial	
membrane	depolarization,	leading	to	higher	levels	of	ROS	induction	61.		
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Degradation	of	NP	in	a	physiological	environment	might	also	lead	to	adverse	effects.	After	
endocytosic	uptake,	the	NP	are	exposed	to	an	oxidative	environment	in	late	endosomes	or	
lysosomes.	 Here	 they	 face	 degrading	 enzymes	 like	 cathepsin	 L	 and	 a	 pH	 of	 5.9	 in	 late	
endosomes	or	4.5	in	lysosomes	40,	62.	This	might	cause	degradation	or	dissolution	of	the	NP	
resulting	in	the	leaching	of	free	ions	40.	The	effect	on	cell	wellbeing	depends	on	the	chemical	
composition	of	the	NP.	For	Cd‐containing	QD,	for	example,	the	leaching	of	highly	toxic	Cd2+‐
ions	is	considered	to	be	the	main	cause	of	any	observed	toxicity	63,	64.		
Finally,	it	is	known	that	NP	can	interact	with	their	environment	and	in	most	cases	avidly	bind	
serum	proteins	to	their	surface	to	form	a	protein	corona	65.	The	nature	of	this	corona	depends	
on	 the	 physicochemical	 properties	 of	 the	 NP	 and	 on	 the	 composition	 of	 the	
microenvironment	(e.g.	cell	culture	media)	surrounding	the	NP	31,	66.	The	binding	of	serum	
proteins	to	the	NP	is	an	important	determinant	in	how	the	cells	‘see’	the	NP	and	therefore	
influences	NP	uptake	and	toxicity	67‐69.	The	proteins	forming	the	corona	might	furthermore	
undergo	conformational	changes,	because	of	which	the	cell	may	see	them	as	an	antigen	and	
initiate	an	 immune	 response	 20,	30.	The	protein	 corona	can	also	 stimulate	opsonisation	by	
macrophages	 in	vivo,	 thereby	 activating	 the	 complement	 system	and	 evoking	 an	 immune	
reaction	70.	Another	plausible	pathway	to	immunotoxicity	is	the	enhancement	of	an	allergic	
immune	 response,	 which	 by	 Nygaard	 et	 al.	 observed	 for	 single‐	 and	 multi‐walled	
carbonnotubes	(CNT)	in	mice	71,	72.		
In	the	current	nanotoxicity	paradigm,	ROS	induction	has	thus	been	set	forth	as	the	main	toxic	
effect	 caused	 by	 NP,	which	may	 (when	 sustained)	 lead	 to	 secondary	 effects.	 Other	 often	
observed	 toxicological	 responses	 are	 morphological	 alterations,	 genotoxicity,	
immunotoxicity	and	effects	 caused	by	 leached	 ions.	Each	of	 these	potential	effects	 should	
consequently	 be	 addressed	 when	 evaluating	 nanotoxicity,	 implying	 the	 need	 to	 evaluate	
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multiple	parameters	via	a	multiparametric	method.	Here	we	will	discuss	the	principles	for	in	
vitro	 and	 in	 vivo	 routine	 methods	 as	 well	 as	 the	 main	 shortcomings	 to	 these	 methods.	
Subsequently	novel	principles,	methods	and	future	prospects	will	be	discussed.	
	
2.2.	Routine	methods	for	nanotoxicity	testing		
In	order	to	obtain	a	complete	toxicological	profile,	NP	toxicity	should	be	evaluated	in	vitro	as	
well	as	in	vivo	73,	74.	The	in	vitro	methods	are	most	commonly	used	and	typically	precede	any	
in	vivo	work.	It	is	essential	to	note	however,	that	prior	to	any	toxicity	testing,	the	NP	must	be	
thoroughly	characterized	with	respect	to	their	purity	(chemical	and	biological	contaminants)	
and	physicochemical	properties	both	in	a	dry	and	wet	state	42,	74.	More	detailed	information	
on	 characterisation	 of	NP	will	 not	 be	provided	here	 as	 this	 falls	 beyond	 the	 scope	 of	 the	
current	 review	but	 can	be	 found	 in	overviews	elsewhere	 42,	 75‐77.	 In	 this	 section	 the	main	
methodological	principles	for	in	in	vitro	and	in	vivo	nanotoxicity	evaluation	will	be	reviewed	
as	well	as	the	most	important	shortcomings	of	these	methods.	
	 	
a.	Routine	in	vitro	methods	
In	vitro	assays	are	mainly	the	first	to	be	conducted	during	a	toxicological	evaluation	78.	Most	
in	vitro	studies	are	conducted	in	classical	2D	monocultures	of	cancer	or	long‐lived	cell	lines	
although	 the	 use	 of	 stem	 cells	 or	 primary	 cells	 is	 steadily	 increasing.	 The	 selection	 of	 a	
relevant	 cell	 type	and	source	generally	depends	on	 the	expected	 in	vivo	 target	organ	and	
application	of	the	NP	79.	In	the	vast	majority	of	the	studies	the	cells	are	exposed	to	the	NP	
dispersion	 during	 a	 single	 incubation	 period	 ranging	 from	 3	 up	 to	 48	 hours	 78,	 80,	 81.		
Afterwards,	the	induced	toxicity	is	evaluated	with	methods	that	were	initially	optimised	for	
toxicity	 assessment	 of	 chemical	 substances	 82.	 Biochemical	 assays	with	 a	 fluorometric	 or	
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spectrophotometric	read‐out,	including	enzymatic	and	(enzyme‐linked)	immunoassays,	are	
used	 to	 the	 utmost	 extend	 due	 to	 the	 relatively	 short	 duration	 of	 most	 assays,	 the	
uncomplicated	detection	principle	and	straight	forward	data	processing	83.	Furthermore	the	
possibility	of	upscaling	and	automation	of	the	execution,	detection	and	data	processing	make	
these	assays	highly	convenient	with	regard	to	a	future	high	content	screening	approach	for	
every	newly	 synthetized	NP	 83,	 84.	Another	popular	 approach	 is	 staining	 the	 entire	 cell	 or	
specific	 cellular	 components	 with	 cellular	 dyes,	 fluorescently	 labeled	 antibodies	 (AB)	 or	
molecular	probes,	which	will	interact	with	a	specific	biomolecule	40,	78,	85.	The	samples	can	on	
the	one	hand	be	analyzed	using	a	plate	reader,	but	if	information	is	requested	on	the	variation	
between	 different	 cell	 types	 or	 status	 (e.g.	 apoptotic	 or	 not),	 flow	 cytometry	 is	 a	 more	
commonly	 used	 technique	 86‐89.	 On	 the	 other	 hand	 microscopic	 analysis	 can	 also	 be	
performed.	This	is	an	important	tool	for	evaluating	morphological	features	like	cell	spreading	
but	will	 also	 increasingly	 be	 applied	 to	 evaluate	 cellular	 processes	 in	 the	 context	 of	 high	
content	screening	90,	91.	The	use	of	such	stainings	in	combination	with	microscopy	however	
mostly	 generates	 qualitative	 or	 semi‐quantitative	 data.	 In	 order	 to	 generate	 quantitative	
data,	other	easily	quantifiable	assays	are	required	as	for	example	the	comet	assay,	PCR	or	
microarrays	to	evaluate	DNA	damage	78.		
Finally	 specialized	 techniques	 are	 used	 to	 evaluate	 specific	 parameters.	 For	 example,	 ion	
leaching	can	either	be	detected	in	cell‐free	conditions	using	specialized	buffers	(pH	7.4;	5.5	
and	 4.5)	 and	 the	 intactness	 of	 stem	 cell	 functionality	 can	 be	 evaluated	 by	 observing	 the	
efficiency	of	cellular	differentiation	induced	by	specific	protocols	40,	92.		
	
	 b.	Routine	in	vivo	methods	
Subsequently	 in	vivo	 studies	 can	be	performed	 testing	a	dose	 range	derived	 from	 in	vitro	
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experiments	or	realistic	exposure	doses	82.	Most	studies,	certainly	preliminary	studies,	are	
conducted	 on	 rodents	 as	 costs	 are	 lower,	 animals	 easier	 to	 access	 and	 infrastructural	
requirements	less	elaborate	73.	Official	instancies	have	determined	the	species	and	number	
of	animals	and	that	should	be	used	for	a	specific	tests,	to	meet	the	incentive	to	reduce	the	
number	of	animals	used	as	urged	by	the	3R	concept	by	Russel	and	Burch,	ethical	criticism	
and	 the	 pressure	 to	 develop	 a	more	 cost‐effective	 toxicity	 assessment	 protocol	 93,	 94.	 The	
European	Commission	has	bundled	 it’s	 guidelines	 in	 the	REACH	(Registration,	Evaluation	
and	 Administration	 of	 Chemicals)	 regulation.	 Even	 though	 this	 regulation	 was	 initially	
designed	for	chemical	substances	it	was	plainly	adopted	to	nanotoxicity	evaluation	95.	The	
approach	of	simply	adopting	REACH	regulations	to	NP	has	however	been	put	to	question	as	
classical	 toxicity	 assays	 show	major	 shortcomings	when	 they	 are	 applied	 to	 nanotoxicity	
assessment,	as	will	be	discussed	in	section	2.4.	For	assay	protocols	REACH	in	turn	refers	to	
the	 guidelines	 drafted	 by	 the	 Organisation	 of	 Economic	 Co‐operation	 and	 Development	
(OECD),	which	will	not	be	discussed	in	detail	but	can	be	found	in	the	‘Preliminary	Review	of	
OECD	Test	Guidelines	for	their	Applicability	to	Manufactured	Nanomaterials’	94.		
When	assessing	nanotoxicity	in	vivo,	the	following	aspects	ought	to	be	evaluated	according	
to	 REACH	 guidelines:	 acute,	 subchronic	 and	 chronic	 toxicity,	 skin	 and	 eye	 irritation	 or	
corrosion	and	skin	sensitisation,	genotoxicity,	reproductive	toxicity,	carcinogenicity	and	the	
NP’s	toxicokinetics	94.	An	overview	of	the	parameters	that	are	evaluated	in	an	in	vitro	or	in	
vivo	setting	is	given	in	table	1.	
A	 commonly	 used	 technique	 for	 in	 vivo	 studies	 is	 the	 histopathological	 examination	 of	
selected	 organs	 and	 tissues	 from	 a	 sacrificed	 animal,	 often	 in	 combination	 with	 an	
appropriate	staining	94.	This	technique	is	used	for	all	required	aspects	except	for	the	skin	and	
eye	 irritation	 or	 corrosion	 and	 skin	 sensitisation	 and	 genotoxicity	 experiments	 94,	 96‐98.	
12	
	
Examination	of	the	organs	includes	an	evaluation	of	its	morphology	in	term	of	length,	width	
and	shape.	Any	changes	in	tissue	colour	must	also	be	documented	94.	Not	only	whole	organs	
are	analysed	as	any	assay	performed	in	an	in	vitro	setting	can	be	performed	on	cells	from	a	
(sacrificed)	animal.	This	way,	more	detailed	information	on	ROS	induction,	inflammation	or	
activation	of	the	immune	system	in	vivo	can	be	obtained.	General	in	vivo	observed	effects	can	
then	be	 clarified	 by	 the	molecular	mechanism	 found	 in	 in	vitro	 experiments.	REACH	also	
requires	blood	and	urine	samples	to	be	taken	at	regular	time	points,	the	weight	of	the	animal	
to	 be	 documented	 as	 well	 as	 its	 behaviour	 and	 food	 and	 water	 consumption	 94.	 When	
performing	 carcinogenicity	 experiments	 the	 endpoint	 of	 the	 study	 is	 the	 appearance	 of	
tumours.	These	can	subsequently	be	resected	and	analysed	in	terms	of	number,	size,	shape	
etc.	99.	These	experiments	are	often	combined	with	long	term	in	vivo	studies	as	proposed	by	
the	OECD	to	further	reduce	the	number	of	animals	needed	100.	
	 In	vitro	 In	vivo	
Acute	toxicity	 X	 X	
Subchronic	toxicity	 	 X	
Chronic	toxicity	 	 X	
Oxidative	stress	 X	 	
Morphology	 X	 X	
Skin	irritation/corrosion	and	eye	
irritation	
X	 *	
Immunotoxicity	and	sensitization	 	 X	
Genotoxicity	 X	 X	
Carcinogenicity	 	 X	
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Reproductive	toxicity	 	 X	
Toxicokinetics	 	 X	
Table	1:	assays	performed	in	an	in	vitro	and	in	vivo	setting.	
*As	 validated	 alternative	methods	 are	 available,	 these	must	 be	 used	 according	 to	REACH	
regulation.	
	
	 c.	Issues	with	routine	methods	
Currently,	 methods	 applied	 for	 evaluating	 NP	 toxicity,	 such	 as	 biochemical	 cell	 viability	
assays	and	the	use	of	 fluorescent	markers,	are	adopted	from	routine	methods	 for	 toxicity	
assessment	of	chemical	substances.	The	evaluation	of	NP	toxicity	using	these	common	assays	
has	however	resulted	in	conflicting	data	as	can	be	found	in	reviews	listing	data	on	the	toxicity	
of	a	specific	NP	or	the	correlation	between	the	NP’s	physicochemical	properties	and	the	toxic	
effects	 it	 evokes	 29,	 101‐103.	 This	 led	 to	 an	 increasing	 awareness	 that	 these	 methods,	 and	
especially	 the	 in	vitro	methods,	are	not	as	appropriate	and	well‐suited	 for	nanotoxicology	
purposes	as	was	previously	assumed	82,	93.	Nel	et	al.	have	first	raised	this	thought	in	2006,	
emphasizing	on	the	necessity	to	optimize	the	classical	in	vitro	toxicity	assays	as	they	show	
several	shortcomings	when	they	are	being	applied	for	NP	toxicity	evaluation	28.	We	believe	
that	 the	 major	 issues	 with	 the	 current	 in	 vitro	 methods	 are	 (i)	 the	 lack	 of	 a	 complete	
characterization	of	the	particles,	(ii	)	the	lack	of	standardisation	and	guidelines	on	how	to	
perform	a	toxicological	evaluation	in	vitro,	(iii)		the	possibility	of	NP	interfering	with	the	assay	
and	therefore	lack	of	appropriate	methods	to	evaluate	nanotoxicity	and	(iv)	the	shortcomings	
inherent	to	the	most	used	classical	2D	monocultures	11,	82,	93,	104,	105.	It	is	therefore	clear	that	
further	research	on	the	optimization	of	methods	is	highly	recommended	in	order	to	obtain	
reproducible	 data	 that	would	 allow	drawing	 firm	 conclusions	 regarding	NP	 toxicity.	 This	
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section	provides	an	overview	of	issues	with	routine	methods,	which	are	not	correlated	to	the	
cultivation	system,	as	these	will	be	the	topic	of	section	3	until	6.		
	 Issues	with	routine	in	vitro	methods	
A	 first	 shortcoming	 to	 the	 current	 nanotoxicity	 testing	 strategy	 is	 the	 lack	 of	 a	 complete	
characterisation	of	the	particles,	as	many	parameters	such	as	NP	size,	charge,	shape	etc.	often	
differ	between	studies	rendering	it	nearly	impossible	to	retrieve	reliable	conclusions	on	the	
effect	of	a	specific	parameter.	This	originates	from	the	fact	that	altering	one	physicochemical	
parameter,	 for	 example	 surface	 charge,	 without	 affecting	 any	 other	 (hydrodynamic	 size,	
colloidal	stability,	nature	of	the	coating…)	is	not	an	easy	task	105.	Therefore	a	multitude	of	
parameters,	 that	 might	 potentially	 influence	 the	 outcome,	 must	 be	 optimised	 and	
standardised	as	far	as	possible.	Therefore	consensus	should	be	reached	on	which	parameters	
must	be	characterised	as	well	as	on	the	methods	applied	for	this	purpose.		
Besides	the	NP’s	physicochemical	parameters,	NP	concentration	is	one	of	the	parameters	that	
could	be	worked	on.	Here	consensus	is	needed	on	methods	to	determine	the	concentration	
as	well	as	on	the	unit,	 in	which	this	parameter	should	be	expressed	106,	107.	Expressing	the	
concentration	in	terms	of	mass/volume	is	the	easiest	option,	but	is	however	not	always	the	
most	 relevant	 105.	 Which	 was	 pointed	 out	 in	 a	 review	 by	 Johnston	 et	 al.,	 as	 they	 often	
encountered	 a	 stronger	 toxic	 response	 for	 the	 smaller	 NP	 in	 comparison	 to	 their	 larger	
counterparts	at	similar	mass/volume	doses	38.	It	was	suggested	by	Wittmaack	that	particle	
number/volume	 might	 be	 the	 best	 dose	 metric	 108.	 Other	 groups	 however	 suggested	 to	
express	the	concentration	in	terms	of	surface	area/volume	as	it	is	known	that	toxicological	
responses	depend	on	 the	NP’s	 surface	properties	 and	 that	 the	 surface	 area	 exponentially	
increases	with	a	decrease	in	NP	size	45,	106,	109.	The	applicability	of	this	unit	was	demonstrated	
by	 Rushton	 et	 al.	 who	 found	 a	 significant	 correlation	 between	 the	 oxidative	 response	
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observed	in	vitro	and	the	in	vivo	inflammatory	response	for	a	group	of	nine	different	NP,	with	
distinct	 physicochemical	 properties,	 when	 the	 concentration	 was	 expressed	 in	 surface	
area/volume	and	the	steepest	slope	method	was	applied	110.	When	the	same	group	applied	
this	method	to	results	from	Sayes	et	al.,	who	could	not	obtain	an	in	vitro‐in	vivo	correlation	
back	 in	2007,	a	 clear	correlation	was	now	established110,	111.	Han	et	al.	 also	 found	a	clear	
correlation	 when	 comparing	 the	 oxidative	 stress	 in	 vitro	 and	 the	 in	 vivo	 inflammatory	
response	after	TiO2NP	exposure,	confirming	the	applicability	of	the	steepest	slope	method	
using	surface	area/volume	as		dose	metric	112.		
Subsequently	 attention	 should	 go	 to	 standardisation	 of	 nanotoxicity	methods	 in	 terms	 of	
incubation	conditions	like	NP	concentration	and	incubation	time	as	overexposure	conditions	
should	be	avoided	113.	The	importance	of	avoiding	overexposure	conditions	becomes	clear	
when	 evaluating	 genotoxicity	 for	 example,	 as	 acute	 toxicity	 at	 overexposure	 levels	 can	
mistakenly	be	interpreted	for	genotoxicity	since	apoptosis	itself	induces	DNA	fragmentation	
114,	115.	This	implies	the	need	to	screen	for	genotoxicity	at	sublethal	levels.	The	determination	
of	 relevant	 dose	 ranges	 is	 however	 severely	 hampered	 by	 the	 lack	 of	 exposure	 data	 and	
required	doses	of	NP	for	specific	applications.	Therefore	in	vitro	(and	in	vivo)	toxicity	testing	
currently	focuses	on	determination	of	the	No	Observed	Adverse	Effect	Level	(NOAEL)	values	
instead	 of	 evaluating	 realistic	 exposure	 scenarios	 or	 dosages	 38.	 This	 may	 lead	 to	 an	
overestimation	of	nanotoxicity	as	according	to	Paracelsus’	principle	every	type	of	material	
will	evoke	toxic	effects	at	sufficiently	high	concentrations.	
Another	important	factor	inducing	variation	in	nanotoxicity	data	is	the	medium	in	which	the	
NP	are	dispersed.	This	can	affect	 the	agglomeration	or	aggregation	state	of	 the	NP,	which	
determines	its	behaviour	in	dispersion	and	subsequently	the	uptake	and	toxicity	induced	by	
the	NP	either	in	a	positive	or	negative	way	116,	117.	Therefore	some	groups	have	focussed	on	
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the	 development	 of	 methods	 to	 create	 a	 stable	 and	 uniform	 dispersion	 via	 surface	
modification,	addition	of	surfactants	etc.	118‐120.	But	opposing	opinions	exist	on	whether	NP	
agglomerates	must	be	redispersed	before	addition	 to	 the	cells	or	not	since	results	 from	a	
study	by	Oberdörster	et	al.	 in	which	surfactant	stabilised	dispersions	were	used,	has	been	
put	to	question	as	the	observed	toxicity	might	have	been	caused	by	surfactant	residuals	121.	
It	 is	 therefore	presumed	 that	 it	 is	best	not	 to	alter	 the	dispersion	state	before	adding	 the	
dispersion	to	the	cell	culture	but	to	strive	for	a	medium	resembling	the	in	vivo	situation	as	
close	as	possible	122,	123.		
A	fourth	major	issue	with	in	vitro	toxicity	assays	is	the	potential	of	NP	to	interfere	with	the	
assay	in	various	ways	82.	Obviously	NP	with	optical	properties	might	alter	the	outcome	of	an	
assay	based	on	a	spectrophotometric	or	fluorometric	read‐out	33.	Other	possible	interference	
mechanisms	are	 interactions	with	 enzymes	or	 substrates	because	of	 the	high	absorbance	
capacity	and/or	catalytic	activity	of	the	NP	82,	104.	Han	et	al.	saw	this	for	AgNP	and	TiO2NP,	
which	respectively	 inactivated	and	adsorbed	to	LDH	 leading	 to	an	underestimation	of	 the	
acute	toxicity	124.	Kroll	et	al.	 looked	into	the	interference	of	24	well‐characterised	NP	with	
four	 frequently	used	 in	vitro	assays	and	observed	concentration,	NP	and	assay‐dependent	
interferences	 32.	 These	 data	 underscore	 the	 importance	 of	 validating	 the	 assays	 for	 each	
specific	type	of	NP.	Until	then,	researchers	must	assure	that	the	measured	toxicity	or	the	lack	
of	toxicity	is	indeed	caused	by	the	NP	and	is	not	merely	a	consequence	of	interference	with	
the	assay,	which	can	be	done	by	introducing	appropriate	controls	125,	126.	Besides	a	negative	
(no	 treatment)	and	positive	control	 (maximum	effect),	which	should	be	 included	 in	every	
assay	when	possible,	the	positive	control	can	also	be	tested	in	combination	with	the	NP.	The	
reagents	 should	 also	 be	 incubated	 with	 the	 NP	 to	 rule	 out	 any	 possible	 interaction	 127.	
Damoiseaux	et	al.	further	suggest	the	use	of	multiple	assays	for	a	single	parameter	to	validate	
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the	obtained	results.	Ideally	the	assays	must	supply	complementary	information	and	have	a	
different	assay‐	and	detection	principle	128.		
Issues	with	routine	in	vivo	methods	
The	 standard	 methods	 for	 in	 vivo	 toxicity	 evaluation	 seem	 to	 be	 more	 applicable	 for	
nanotoxicity	assessment:	NP	do	not	seem	to	influence	the	obtained	results	as	gravely	since	
there	are	no	present	reports	on	NP	interacting	with	the	assays,	although	scepticisms	has	been	
raised	on	the	subject.	In	this	context	the	fewer	number	of	in	vivo	studies	must	be	considered,	
as	interactions	may	not	have	been	uncovered	yet.		
The	major	 issue	for	 in	vivo	nanotoxicity	testing	 is	the	set	up	of	a	relevant	dose	range	that	
mimics	 actual	 human	 exposure	 to	NP	 82.	 This	 issue	 is	 very	 complex	 since	 total	 exposure	
includes	intentional	and	unintentional	exposure	for	consumers	as	well	as	for	workers	at	the	
production	site	via	different	exposure	routes	with	the	respiratory	system,	the	GI	tract	and	
the	skin	being	 the	main	portals	of	entry	 11,	74,	115.	Additionally	exposure	may	occur	during	
every	stage	of	the	NP’s	lifecycle,	being	the	development,	manufacturing,	use	and	disposal	of	
the	NP	123.	The	extent	and	complexity	of	this	problem	thus	requires	a	case‐by‐case	division	
into	multiple	scenarios	so	total	exposure	for	a	specific	group	can	be	reconstructed	from	the	
categorical	exposure	doses.	The	determination	of	these	doses	is	however	highly	impeded	by	
the	 lack	 of	 validated	methods,	 which	 allow	measuring	 exposure	 doses	 in	 a	 standardised	
manner	in	different	settings.		
Inhalation	studies	are	regarded	as	the	‘golden	standard’	for	in	vivo	nanotoxicity	studies	as	
exposure	via	this	route	is	expected	to	be	the	most	abundant	and	exposure	to	airborne	NP	has	
already	been	associated	with	adverse	health	effects	129.	Therefore	most	of	the	relatively	low	
number	of	conducted	 in	vivo	studies	considered	toxicity	after	pulmonary	exposure.	But	as	
currently	 no	 standard	 protocols	 are	 available	 for	 this	 type	 of	 study,	 optimization	 is	 still	
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required.	 Several	 groups	 have	 therefore	made	 efforts	 to	 optimise	 various	 aspects	 of	 the	
protocol	with	the	major	hurdle	being	the	preparation	of	the	aerosols,	as	NP	tend	to	aggregate	
because	of	their	strong	hydrophobic	properties	84,	130.	The	same	issue	of	sample	preparation	
also	occurs	for	studies	exploring	other	portals	of	entry.	Therefore	a	number	of	groups	have	
focused	 on	 developing	methods	 to	 create	 stable	 and	 uniform	 dispersions	 in	 a	 controlled	
manner.	 But	 similar	 as	 for	 in	 vitro	 experiments	 it	 has	 been	 put	 to	 question	whether	 the	
agglomerates	should	be	redispersed	prior	to	administration	and	so	far	no	consensus	has	been	
reached	on	the	subject	130.	Another	shortcoming	parallel	to	 in	vitro	studies	is	the	lack	of	a	
complete	characterization	of	the	evaluated	NP	so	no	clear	correlations	between	the	observed	
effect	and	the	physicochemical	properties	of	the	NP	can	be	formulated.		
Subsequently,	detection	strategies	are	correlated	to	the	type	of	NP	tested	and	may	therefore	
differ	for	different	types	of	NP.	Fluorescent	NP	can	for	example	easily	be	detected	but	other	
NP	will	need	to	be	linked	with	a	fluorescent	probe	to	allow	detection	by	the	same	methods.		
This	strategy	might	however	not	be	the	most	suitable,	as	the	formation	of	the	protein	corona	
and	interaction	with	biomolecules	might	be	altered	because	of	this	probe	and	therefore	alter	
its	 in	vivo	 behaviour	and	 toxicological	profile	 74.	 Finally,	methods	 should	be	developed	 to	
obtain	information	on	the	stability	of	the	NP	in	vivo	to	see	whether	NP	remain	unimpaired	or	
undergo	degradation	as	this	will	influence	the	observed	toxicity	and	may	elucidate	toxicity	
mechanisms	31.	
Overviewing	 these	 findings,	 it	 can	be	 concluded	 that	 routine	 in	vitro	 and	 in	vivo	methods	
suffer	from	the	same	artefacts	when	they	are	applied	for	nanotoxicity	evaluation,	without	any	
modifications	to	the	protocols	to	fit	this	new	purpose.	One	of	the	most	important	issues	is	the	
setup	of	a	representative	dose	range	based	on	realistic	exposure	scenarios	in	both	the	in	vitro	
and	in	vivo	setting.	The	issue	of	selecting	the	most	suitable	dose	metric	is	only	mentioned	for	
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the	in	vitro	experiments	but	is	likely	to	also	account	for	the	in	vivo	situation.	The	same	is	true	
for	the	issue	of	NP	characterisation	as	thorough	characterisation	is	always	inevitable	in	order	
to	allow	drawing	firm	conclusions.	Aggregation	of	NP	in	dispersion	media	is	another	issue	
that	also	occurs	on	both	levels	of	toxicity	testing	and	so	does	the	possible	interferences	with	
the	assays	used.	In	vivo	methods	show	an	additional	shortcoming,	as	detection	strategies	are	
not	always	the	most	suites	so	the	need	for	novel	methodologies	becomes	more	prominent.	
Thus,	 it	 can	be	 stated	 that	both	 in	vitro	and	 in	vivo	methods	 cannot	be	plainly	 applied	 to	
nanotoxicity	studies	and	that	the	entire	nanotoxicity	testing	paradigm	should	be	subject	to	
thorough	 optimization,	 which	 has	 been	 stimulated	 by	 the	 combined	 efforts	 of	 various	
research	groups.		
	
2.3.	Novel	methods	for	toxicity	testing		
Recently,	 a	 number	 of	 groups	 have	 pointed	 out	 several	 shortcomings	 to	 the	 current	
nanotoxicity	methods	and	the	corresponding	need	for	optimization	(see	2.2.c).	Especially	the	
optimization	of	in	vitro	methods	receives	a	lot	of	attention	since	they	will	be	the	basis	of	a	
future	screening	approach,	which	is	highly	needed	to	keep	up	with	the	rapid	pace	at	which	
the	entire	 field	of	nanotechnology	keeps	evolving.	This	section	provides	a	number	of	new	
insights	 and	 methods	 for	 nanotoxicity	 assessment,	 guided	 by	 examples	 from	 recent	
literature.		
	
	
	
a.	Particokinetics	
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As	mentioned	in	section	2.2.c.	NP	dosimetry	poses	several	challenges.	To	meet	this	challenge	
Teeguarden	 et	 al.	 proposed	 the	 concept	 of	 particokinetics,	 representing	 the	 solution	
dynamics	 of	 the	 NP	 116.	 They	 marked	 diffusion,	 sedimentation	 and	 aggregation	 as	
predominant	 processes	 determining	 the	 NP’s	 faith	 in	 dispersion.	 Subsequently	 they	
suggested	a	distinction	between	the	administered,	delivered	and	cellular	dose	respectively	
being	 the	 dose	 added	 to	 the	 cell	 culture,	 the	 dose	 reaching	 the	 cell	 surface	 and	 the	 dose	
actually	reaching	the	interior	of	the	cell	(Figure	1).	The	latter	dose	is	the	most	interesting	for	
nanotoxicity	and	cell	 labelling	studies	but	 is	also	 the	hardest	 to	determine.	Until	methods	
become	 available	 to	 determine	 the	 cellular	 dose	 in	 vitro,	 preferably	 in	 real‐time,	 they	
proposed	the	application	of	a	model	that	enables	the	calculation	of	the	delivered	or	cellular	
dose	starting	from	the	administrated	dose	and	the	behaviour	of	the	NP	in	dispersion	116.	This	
model	was	recently	optimized	by	Hinderliter	et	al.	and	is	since	then	referred	to	as	the	In	vitro	
Sedimentation,	Diffusion	and	Dosimetry	model	or	ISDD	131.	Lison	et	al.	however	believe	that	
the	hereby‐calculated	doses	will	be	underestimated	for	monodisperse	NP	suspensions	since	
this	model	does	not	take	convectional	forces	into	account,	which	mostly	develop	in	solutions	
132.		
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Figure	1:	 Schematic	 representation	 of	 the	 concept	 of	administered	dose	 (a),	delivered	dose	 (b)	and	
cellular	dose	(c).	
	
b.	Multiparametric	nanotoxicity	evaluation	
Since	it	was	observed	that	NP	can	cause	multiple	effects	via	different	mechanisms,	awareness	
has	risen	on	the	necessity	to	evaluate	nanotoxicity	in	vitro	by	a	multiparametric	method	43,	83.	
This	 method	 should	 include	 the	 evaluation	 of	 different	 endpoints	 via	 multiple	 assays	
preferably	in	multiple	cell	types	from	different	organisms	to	increase	the	predictive	power	
128,	 133,	 134.	 	 Endpoints	 like	 acute	 toxicity,	 ROS	 induction,	 morphological	 alterations,	
genotoxicity	and	NP	degradation	have	been	put	forward	as	important	parameters	40,	128,	133	.	
Consensus	on	the	optimal	design	of	this	multiparametric	method	has	however	not	yet	been	
reached,	but	several	examples	have	been	proposed	recently,	including	one	from	our	group	
that	is	displayed	in	figure	2	43,	127.	Methods	to	evaluate	the	different	parameters	are	preferably	
biochemical	or	microscopy‐based	assays	as	they	are	easily	amendable	for	a	future	screening	
approach	128.	Some	groups	also	suggest	the	implementation	of	omic‐techniques	to	screen	for	
genotoxicity,	alterations	in	protein	expression	or	biomarkers	related	to	cellular	pathways	84,	
135.	Any	multiparametric	method	shall	require	a	high	content	screening	(HCS)	setup	to	enable	
simultaneous	 testing	of	multiple	doses	 in	different	 cell	 types	by	using	various	assays	 in	a	
reasonable	amount	of	time	128,	133.	This	screening	approach	appears	to	be	very	promising	as	
O’Brien	 et	al.	 found	 a	 sensitivity	 and	 specificity	 of	 respectively	 93%	 and	 98%	 for	 a	 five‐
parameter	 HCS	 method	 in	 comparison	 to	 a	 single	 parameter	 approach	 that	 showed	 a	
sensitivity	 of	 25%	 136.	 Jan	 et	 al.	 furthermore	 demonstrated	 the	 applicability	 of	 HCS	 in	
establishing	nanotoxicity	profiles,	underscoring	the	potential	of	this	approach	137.		
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Figure	2:	Schematic	overview	of	the	multiparametric	method	developed	by	Soenen	et	al.	
c.	QSAR	and	in	silico	models	
These	screening	approaches	will	generate	a	vast	amount	of	data	at	a	high	pace,	causing	the	
bottleneck	 of	 nanotoxicity	 testing	 to	 shift	 from	 the	 assay	 execution	 to	 data	 processing.	
Therefore	 bio‐informatics	 are	 gaining	 importance	 as	 an	 automated	 data	 analysis	 will	 be	
necessary	to	be	able	to	keep	up	with	the	rapidly	evolving	field	of	nanotechnology	134.		
A	popular	subject	in	bio‐informatics	is	the	set	up	of	an	in	silico	approach	to	nanotoxicity	with	
the	development	of	quantitative	structure‐activity	relationships	(QSAR)	as	the	ultimate	goal.	
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These	QSARs	will	in	turn	allow	the	prediction	of	the	toxicity	of	newly	engineered	NP	based	
on	 their	 physicochemical	 properties	 enabling	 an	 even	 faster	 evolution	of	nanotechnology	
through	a	 safety‐by‐design	approach	 134.	The	development	of	 in	 silico	models	and	HCS	go	
hand	in	hand	as	on	the	one	hand	the	development	of	a	reliable	in	silico	model	requires	a	large	
amount	of	data,	which	can	be	provided	by	HCS,	and	on	the	other	hand	bio‐informatic	tools	
are	indispensible	for	an	efficient	processing	of	HCS	data	134.	Recently	efforts	from	Puzyn	et	al.	
have	resulted	in	the	development	of	a	QSAR	predicting	the	toxicity	of	metal	oxide	NP	in	E.	
Coli	based	on	the	effect	of	17	different	metal	oxide	NP	138.	However,	many	obstacles	still	need	
to	be	overcome	before	the	first	QSAR	can	be	implemented	that	allows	the	prediction	of	the	
adverse	effects	of	any	NP	towards	human	health.	Therefore,	clear	correlations	between	the	
NP’s	physicochemical	properties	and	observed	effect	must	be	found,	large‐scale	comparative	
studies	 should	 be	 performed	 and	 the	 QSARs	 must	 be	 validated,	 which	 requires	 the	
indentification	of	reference	nanomaterials	with	well‐known	effects	40,	83.		
	
	
	
d.	Novel	in	vivo	methods	
Novelties	 to	 in	 vivo	 methods	 are	 not	 as	 numerous	 as	 for	 their	 in	 vitro	 counterparts,	 but	
recently	some	research	has	been	performed	on	the	use	of	zebrafish	embryos	for	an	in	vivo	
screening	approach.	Similar	as	for	most	 in	vitro	methods	used	in	nanotoxicity	assessment,	
Hill	 et	 al.	 initially	 developed	 this	 method	 for	 the	 evaluation	 of	 the	 toxicity	 of	 chemical	
substances	 139.	 Usenko	 et	al.	 subsequently	 demonstrated	 the	 suitability	 of	 this	model	 for	
nanotoxicity	 evaluation	 and	 follow‐up	 studies	 examining	 AuNP,	 AgNP	 and	 QD	 toxicity	
underscored	 the	 potential	 of	 this	model	 140,	 141,	 142.	 The	main	 advantages	 to	 other	 in	 vivo	
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models	are	the	reductions	in	cost,	labour,	time	and	infrastructural	requirements	as	zebrafish	
are	small	and	have	a	short	 life	cycle	140.	Another	 important	breakthrough	 is	 the	use	of	an	
integrated	screening	approach	using	the	zebrafish	model	and	HCS	to	obtain	a	hazard	ranking	
of	different	NP,	which	was	recently	proposed	by	George	et	al.	143.	
As	the	field	of	nanotechnology	is	rapidly	evolving,	nanotoxicology	could	not	fall	behind.	The	
most	 important	 innovations	 for	 in	 vitro	 methods	 in	 the	 recent	 years	 are	 the	 concept	 of	
particokinetics	 and	 the	 development	 of	mutiparametric	methods.	 The	 latter	 initiated	 the	
development	 of	 a	 HCS	 approach	 and	 in	 silico	models	with	 QSARS	 and	 a	 safety‐by‐design	
approach	as	the	ultimate	goal.	Innovation	to	in	vivo	experiments	can	be	found	in	the	screening	
approach	using	the	zebrafish	embryomodel,	which	can	subsequently	be	combined	with	 in	
vitro	HCS.	Innovation	off	course	does	not	stop	here,	as	these	methods	require	optimisation	
and	standardisation	and	many	obstacles	still	need	to	be	overcome.	
		
3.	The	nature	of	cell‐type	dependent	effects	
In	vitro	studies	are	mostly	performed	on	cancer	cell	lines	or	long‐lived	cell	lines	as	these	are	
readily	available,	 relatively	 inexpensive	and	easy	 to	cultivate	as	 they	exhibit	an	enhanced	
proliferative	capacity.	Yet,	it	is	known	that	cancer	cells	show	a	disturbed	apoptotic	balance	
and	a	higher	metabolic	activity	to	sustain	their	high	proliferation	rate	144.	Long	lived	cell	lines	
in	turn	express	a	phenotype	that	is	not	entirely	stable,	as	changes	may	have	been	induced	
unintentionally	 during	 the	 long	 cultivation	 time	 and	 extensive	 in	 vitro	 manipulation	 or	
intentionally	during	their	immortalization	145,	146.	Alterations	may	include	changes	in	cellular	
homeostasis,	growth	potential,	biological	responses,	signal	transduction	etc.	Hence,	doubts	
have	 been	 raised	 on	whether	 these	 cell	 lines	 are	 a	 reliable	 representation	 of	 the	 in	 vivo	
situation	and	on	their	usefulness	in	NP	hazard	assessment.	Subsequently	the	use	of	primary	
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cells	or	stem	cells	has	been	put	 forward	as	an	alternative	as	 it	 is	assumed	that	these	cells	
stand	closer	to	the	in	vivo	cellular	situation	as	they	undergo	minimal	manipulation	in	vitro	in	
comparison	 to	 cell	 lines	 146,	 147.	 But,	 since	 these	 cells	 are	 not	 always	 easily	 obtained	 and	
require	specific	handling,	this	assumption	first	needs	to	be	proven	by	comparative	studies	in	
order	to	revise	the	current	 in	vitro	 testing	strategy.	Primary	cells	may	 in	turn	suffer	 from	
batch‐to‐batch	differences,	which	could	affect	 the	outcome	of	performed	experiments	and	
thereby	reduce	the	reproducibility	of	the	experiments,	which	is	not	an	issue	with	cell	lines.	
The	use	of	pooled	stocks	may	be	a	good	strategy	to	overcome	these	interbatch	differences	
and	allows	taking	interindividual	variations	into	account,	which	is	in	turn	not	possible	when	
using	cell	lines.	A	summary	of	properties	of	cell	lines	and	primary	cells	or	stem	cells	can	be	
found	in	table	2.		
To	verify	whether	various	cell	types	differ	in	their	way	of	handling	administered	NP	several	
studies	were	 undertaken	 comparing	NP	 uptake	 and	 cytotoxicity	 in	 different	 cell	 types	 of	
which	the	results	will	be	summarized	in	this	section.		
	
Cell	lines	 Primary	or	stem	cells	
Readily	available	 Not	always	readily	available	
Less	expensive	 More	expensive	
Easy	to	cultivate	 Require	specific	handling	
No	interbach	differences	 Interbach	differences	
No	interindividual	differences	 Interindividual	differences	
Much	in	vitro	manipulation	 Minimal	in	vitro	manipulation	
Disturbed	apoptotic	balance	 Normal	
Altered	metabolism		 Normal	
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Altered	phenotype	 Normal	
Enhanced	proliferative	capacity	 Normal	
Table	2:	Comparison	of	features	of	cell	lines	and	primary	or	stem	cells	with	regard	to	their	
properties	important	for	nanotoxicity	studies.	
	
	 3.1.	Effect	of	the	cell	type	on	nanoparticle	uptake	and	processing	
It	 has	 been	 shown	 in	many	 studies	 that	most	NPs	 enter	 the	 cells	 through	 the	 process	 of	
endocytosis.	Some	exceptions	can	be	found	as	for	phagocytotic	cells	phagocytosis	remains	
the	most	important	mechanism	148.	Wang	et	al.	have	furthermore	observed	quantum	dot	(QD)	
uptake	by	passive	diffusion	in	red	blood	cells.	This	must	however	be	put	into	perspective	as	
red	blood	cells	are	not	capable	of	endocytosis	149.	The	uptake	mechanism	is	highly	important	
as	it	determines	the	NP’s	intracellular	location,	as	NP	entering	the	cell	by	passive	diffusion	
directly	interact	with	the	cytosol,	while	NP	taken	up	by	endo‐	or	phagocytosis	are	retained	in	
vesicles	that	are	distributed	widely	in	the	cytoplasm	or	localized	in	a	specific	cellular	region	
149,	150.	Since	the	uptake	kinetics	and	intracellular	location	are	important	determinants	for	the	
final	 toxic	 response	 and	 appear	 to	 differ	 between	 cell	 types,	 several	 studies	 have	 been	
conducted	 comparing	 these	 parameters	 in	 different	 cell	 types.	 For	 example,	 Sur	 et	 al.	
compared	the	uptake	of	AgNP	modified	with	glucose,	lactose	or	oligonucleotides	in	L929	and	
A549	 cell	 lines,	 respectively	 a	 long‐lived	 mouse	 fibroblast	 cell	 line	 and	 a	 human	 lung	
epithelium	cancer	cell	line	and	observed	a	differential	uptake	rate	in	all	cell	lines	with	A549	
cell	showing	the	highest	uptake	of	lactose	modified	NP	151.	Coulter	et	al.	compared	the	uptake	
of	1.9	nm	diameter	AuNP	in	human	prostate	and	breast	cancer	cell	lines	(DU154	and	MDA‐
MB231)	 to	 a	 human	 lung	 epithelium	 long‐lived	 cell	 line	 (L132),	 and	 observed	 the	 lowest	
uptake	in	the	latter	152.	Diaz	et	al.	compared	the	uptake	of	five	different	NP	in	normal	human	
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monocytes,	lymphocytes	and	erythrocytes,	mouse	macrophages	and	four	human	cancer	cell	
lines:	a	myeloid‐monocytic	cell	line	(U937),	a	T‐cell	line	(Jurkat),	a	B‐cell	line	(HMY)	and	a	
prostatic	 cancer	 cell	 line	 (PC3).	 Human	 monocytes	 rapidly	 phagocytosed	 all	 NP	 tested	
whereas	mouse	macrophages	showed	an	even	higher	uptake,	which	was	comparable	to	the	
uptake	in	PC3	cells.	The	monocytic	cell	line	however	did	not	show	NP	internalisation,	which	
conflicts	with	results	from	other	studies	showing	a	higher	uptake	capacity	for	cancer	cell	lines	
151‐153.	 All	 other	 cell	 types	 tested	 did	 not	 show	 a	 significant	 uptake.	 The	 authors	 have	
therefore	 put	 the	 phagocytic	 machinery	 in	 combination	 with	 the	 cell	 type	 forward	 as	
predominant	factors	for	NP	uptake	154.	This	was	supported	by	findings	from	Greulich	et	al.	as	
they	observed	avid	uptake	by	human	primary	monocytes	through	phagocytosis	but	did	not	
find	any	uptake	in	human	primary	lymphocytes	155.		
Wang	 et	 al.	 recently	 evaluated	 the	 intracellular	 distribution	 for	 PEGylated	 micelles	 in	 a	
human	lung	cancer	cell	line	and	long‐lived	cell	line	(A549	and	MRC‐5)	and	a	human	kidney	
epithelium	derived	long‐lived	cell	line	(293T)	which	showed	similar	distributions	144.	Barua	
and	Rege	however	observed	significant	variations	in	intracellular	localisation	of	QD	in	three	
phenotypically	 closely	 related	human	prostate	 cancer	 cell	 lines,	 as	 can	be	deducted	 from	
Figure	3.	It	was	observed	that	the	QD	were	trapped	in	lysosomes	scattered	throughout	the	
cytoplasm	in	PC3	cells,	 localized	at	a	single	 juxtanuclear	 location	in	PC3‐PSMA	cells	and	a	
combination	of	both	was	found	in	PC3‐flu	cells	156.	They	coupled	these	observations	to	the	
loss	of	polarity	in	malignant	cells	influencing	the	sorting	and	trafficking	potency	of	the	cells,	
the	 slight	 differences	 in	 receptor	 expression	profiles	 and	 a	 disruption	 of	 the	microtubule	
network	in	PC3	cells	impeding	further	trafficking	to	the	juxtanuclear	region	156.	
It	can	be	concluded	from	these	data	that	cellular	uptake	and	distribution	of	NP	depends	on	
many	 factors	 like	 the	difference	 in	 precise	 uptake	mechanism,	which	 is	 in	 turn	 cell	 type‐
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dependent.	Furthermore	uptake	does	not	only	significantly	differ	between	human	or	rodent	
cells,	but	also	between	cancer	or	long‐lived	cell	lines	and	primary	cells	with	cancer	cell	lines	
generally	showing	the	highest	uptake.	Besides	uptake,	cellular	distribution	of	NP	is	cell	type	
dependent	as	well	and	has	even	been	found	to	differ	substantially	between	phenotypically	
closely	related	cell	 lines.	Therefore	 these	 findings	underline	the	 importance	of	selecting	a	
representative	cell	type,	which	mimics	the	in	vivo	situation	as	closely	as	possible,	as	toxicity	
is	logically	related	to	the	uptake	determining	the	cellular	dose	of	the	NP.		
	
Figure	3:	Differential	 intracellular	 localization	of	QDs	 in	human	PCa	cells.	a)	PC3,	b)	PC3‐flu,	c)	PC3‐
PSMA 
	
	 3.2.	Effect	of	the	cell	type	on	NP	toxicity	
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Only	recently	more	awareness	was	raised	on	cell	 type‐dependent	effects	being	one	of	 the	
factors	causing	the	generation	of	discordant	results	in	in	vitro	nanotoxicity	studies.	Therefore	
the	number	of	studies	comparing	NP	effects	in	multiple	cell	types	is	relatively	low.	Similar	as	
for	uptake	studies,	some	groups	have	focussed	on	comparing	several	cell	lines.	A	recent	study	
by	 Chowdbury	 et	al.	 provides	 a	 comparison	 between	 two	 human	 breast	 cancer	 cell	 lines	
(SKBR3	and	MCF7),	a	cervical	cancer	cell	line	(HeLa)	and	a	mouse	fibroblast	long‐lived	cell	
line	(NIH‐3T3).	HeLa	cells	appeared	to	be	the	most	sensitive	to	toxicity	induced	by	oxidized	
graphene	nanoribbons,	which	could	be	linked	to	the	higher	uptake	157.	Xia	et	al.	examined	the	
toxicity	of	cationic	polystyrene	NP	in	3	rodent	cancer	cell	lines:	RAW	264.7	(mouse	leukemic	
monocyte	macrophage),	HEPA‐1	(mouse	hepatoma)	and	PC12	(rat	pheochromocytoma);	and	
2	human	 long‐lived	cell	 lines:	BEAS‐2B	 (human	bronchial	 epithelium)	and	HMEC	 (human	
micro‐vascular	endothelial).	All	cell	lines	showed	NP	uptake	but	only	RAW	264.7	and	BEAS‐
2B	cell	lines	were	prone	to	NP	toxicity	and	respectively	suffered	apoptosis	and	necrosis	while	
other	cell	lines	were	relatively	resistant	to	particle	injury	158.		
As	the	use	of	cell	lines	for	in	vitro	nanotoxicity	assessment	has	been	put	to	question,	several	
groups	rather	focussed	on	comparing	the	effects	of	NP	exposure	in	cell	lines	and	primary	or	
stem	cells	representing	the	same	tissue.	For	instance,	Albrecht	et	al.	compared	NP	toxicity	in	
primary	rat	alveolar	macrophages	to	a	rat	alveolar	macrophage	long‐lived	cell	line	(NR8383)	
and	found	the	latter	to	be	more	sensitive	145.		Wang	et	al.	found	primary	catfish	hepatocytes	
to	be	less	sensitive	to	CuONP	and	ZnONP	induced	toxicity	than	cells	from	the	human	HepG2	
hepatoma	cell	 line	 159.	When	Wang	et	al.	 compared	the	 toxicity	of	FITC‐encapsulated	SiO2	
core/ZnO	 shell	 NP	 in	 the	 Jurkat	 cell	 line	 and	 primary	 T‐lymphocytes,	 which	 were	 less	
sensitive	 to	 nanotoxicity	 160.	 Hanley	 et	 al.	 compared	 ZnONP	 induced	 toxicity	 in	 human	
primary	T‐cells	and	two	human	T‐cell	lymphoma	cell	lines	(Jurkat	and	Hut‐78)	and	found	the	
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two	 cell	 lines	 to	 be	 respectively	 28‐	 and	 35‐fold	more	 sensitive	 to	 ZnONP	 exposure	 than	
normal	T‐cells	(Figure	4a)	161.	In	contrast	to	these	studies	Bregoli	et	al.	observed	an	impaired	
proliferation	in	primary	human	hematopoietic	progenitor	cells	after	Sb2O3NP	exposure	while	
the	proliferative	capacity	of	none	of	the	seven	hematopoietic	(cancer	and	long‐lived)	cell	lines	
tested	was	affected	146.		
Several	comparative	studies	have	furthermore	tried	to	elucidate	the	mechanisms	behind	the	
differential	reactions	to	NP	exposure.	First,	the	degree	of	association	between	the	NP	and	the	
cell	membrane	is	known	to	be	crucial	as	it	influences	NP	uptake	levels	161.	The	physiological	
function	of	the	cell	also	appears	to	be	important	with	regard	to	NP	uptake,	as	for	example	
macrophages	and	monocytes	mostly	show	higher	uptake	and	are	therefore	more	susceptible	
to	nanotoxicity,	which	can	be	linked	to	the	phagocytotic	uptake	mechanism	and	the	capacity	
to	 clear	 xenobiotics	 from	 the	 body	 154,	 155,	 162.	 Another	 factor	 determining	 the	differential	
sensitivity	to	nanotoxicity	in	various	cell	lines	is	the	variation	in	proliferative	capacity.	Chang	
et	al.	compared	three	long‐lived	fibroblast	cell	lines	(WS1,	CCD‐966sk	and	MRC‐5)	to	three	
epithelial	cancer	cell	lines	(A549,	MKN‐28	and	HT‐29),	with	average	doubling	times	of	128.4	
and	23h	respectively.	All	three	epithelial	cancer	cell	lines	were	less	prone	to	silica	NP	induced	
injury,	which	may	be	due	 to	 the	higher	rate	of	cell	division	and	 the	associated	dilution	of	
cellular	NP	levels	163.	Another	study	by	Hanley	et	al.	however	showed	a	higher	susceptibility	
to	ZnONP	injury	for	activated	primary	human	T	lymphocytes	in	comparison	to	resting	human	
T	lymphocytes,	as	can	be	seen	in	Figure	4b	161.	This	preferential	targeting	of	rapidly	dividing	
cells	can	in	turn	be	coupled	to	a	higher	uptake	of	the	NPs	in	actively	proliferating	cells	164.	
Furthermore,	Mukherjee	et	al.	 have	put	 the	cells	natural	 antioxidant	 levels	 forward	as	an	
important	factor.	They	coupled	the	higher	susceptibility	of	HeLa	cells	in	comparison	to	HaCaT	
cells	 (a	 human	 dermal	 cancer	 cell	 line)	 towards	 AgNP	 toxicity	 to	 the	 lower	 natural	
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antioxidant	capacity	of	HeLa	cells,	as	AgNP	caused	stronger	ROS	induction	and	GSH	depletion	
in	the	latter	165.	The	natural	antioxidant	levels	being	a	deciding	factor	in	differential	cellular	
responses	 to	 NP	 exposure	 is	 consistent	 with	 as	 ROS	 induction	 being	 the	 main	 common	
mechanism	inducing	nanotoxicity	28.		
Since	the	focus	of	in	vitro	toxicity	testing	is	shifting	to	primary	cells,	Zhang	et	al.	evaluated	
whether	differentiated	or	undifferentiated	primary	human	bronchial	epithelial	cells	showed	
different	 levels	 of	 toxicity	 following	 NP	 treatment.	 By	 evaluating	 toxicity	 via	 a	
multiparametric	method	they	found	the	differentiated	cells	to	be	more	sensitive	to	silica	NP	
induced	injury	166.	Haase	et	al.	recently	evaluated	AuNP	toxicity	in	co‐cultures	consisting	of	
primary	neurons	and	astrocytes	and	also	found	that	more	differentiated	cultures	were	more	
sensitive	to	NP	exposure	167.	Jan	et	al.	obtained	similar	results	studying	QD	toxicity	in	both	
differentiated	and	undifferentiated	NG108‐15	(mouse	neuroblastoma	x	rat	glioma	hybrid)	
cells.	They	explained	their	findings	by	the	fact	that	undifferentiated	cells	show	a	higher	level	
of	adaptability	in	comparison	to	the	differentiated	cells	137.	This	is	supported	by	findings	from	
Saretzki	et	al.	who	found	the	stress	defence	mechanism	(antioxidant	capacity	and	DNA	repair	
mechanism)	in	murine	embryonic	stem	cell	to	be	superior	to	that	of	differentiated	murine	
cells	(fibroblasts,	hematopoietic	progenitor	cells	and	3T3	fibroblast	long‐lived	cell	line)	168.	
These	results	show	higher	sensitivity	of	differentiated	cells	to	NP	induced	injury,	probably	
due	to	the	lower	adaptability	to	their	surroundings.	Therefore	not	only	the	cell	type	but	also	
the	level	of	differentiation	needs	to	be	taken	into	account	when	evaluating	nanotoxicity	in	
vitro.	
It	 is	clear	from	these	data	that	the	response	to	NP	exposure	is	highly	cell	type‐dependent.	
Studies	comparing	sensitivity	to	nanotoxicity	in	primary	cells	and	cell	lines	found	significant	
differences	with	primary	cells	mostly	being	less	sensitive	to	NP	induced	injury	while	cell	lines	
32	
	
were	expected	to	be	more	resilient.	This	can	however	not	be	generalised	as	conflicting	results	
are	published	on	 the	 subject.	 The	 level	 of	 cellular	differentiation	also	 appears	 to	have	an	
influence	 since	 more	 differentiated	 primary	 cells	 were	 found	 to	 be	 more	 susceptible	 to	
nanotoxicity	in	several	studies.	These	differences	in	sensitivity	may	largely	be	explained	by	
variations	 in	 cell	 function	 influencing	 NP	 uptake,	 metabolic	 activity,	 natural	 antioxidant	
activity	 and	 proliferative	 capacity.	 These	 data	 underscore	 the	 importance	 of	 selecting	 a	
relevant	cell	system	for	hazard	assessment,	which	is	a	balancing	act	since	both	primary	cells	
and	 cell	 lines	 show	 specific	 advantages	 and	 major	 shortcomings.	 As	 for	 example	 the	
phenotype	of	differentiated	primary	cells	resembles	the	 in	vivo	 situation	more	closely	but	
keeping	differentiated	cells	in	culture	remains	a	great	challenge.	Therefore	further	research	
is	needed	on	finding	the	right	cell	system	as	well	as	optimization	of	cell	culture	protocols.	
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Figure	4:	(a)	differential	viability	after	NP	exposure	for	Jurkat	and	Hut‐78	cancer	cell	lines	and	normal	
human	T	lymphocytes.	(b)	differential	viability	after	NP	exposure	of	unactivated	and	activated	human	T	
lymphocytes.	
	
4. The	effect	of	particle	agglomeration	and	sedimentation	
In	 a	 similar	 setup	 as	 for	 chemicals,	 NP	 hazard	 is	 mostly	 evaluated	 in	 classical	 2D	
monocultures.	 As	 chemical	 substances	 typically	 dissolve	 in	 the	 cell	 medium,	 the	 dose	 to	
which	the	cells	are	exposed	to	is	accurately	represented	by	the	concentration	of	the	chemical	
in	 the	solution.	 In	 first	 instance	 it	was	assumed	that	 this	also	applied	to	NP,	as	 they	were	
thought	to	be	evenly	dispersed	by	Brownian	motion	35.	But	this	appeared	not	to	be	true	since	
NP	 in	 dispersion	 are	 not	 only	 subject	 to	 diffusion	 but	 also	 to	 sedimentation	 and	
agglomeration	116.	Therefore	the	concept	of	dose	is	more	complex	and	dynamic	for	NP	as	it	is	
for	 chemicals.	 To	 address	 this	 issue	 Teeguarden	 et	 al.	 developed	 the	 concept	 of	
particokinetics	to	model	the	NP	behaviour	in	dispersion	based	on	its	 likelihood	to	diffuse,	
sediment	and	agglomerate	in	dispersion	116,	131.	Since	both	diffusion	and	sedimentation	are	
influenced	by	agglomeration,	the	latter	is	expected	to	have	a	major	impact	on	the	NP	uptake	
and	toxicity	169.	It	is	important	to	note	the	difference	between	agglomeration	and	aggregation	
since	 both	 terms	 are	 often	mixed	 up:	 aggregates	 are	 formed	 by	 covalent	 bonds	 and	 are	
therefore	not	as	easy	to	break	up	as	agglomerates,	which	are	held	together	by	van	der	Waals	
forces,	hydrophobic	interactions	and/or	hydrogen‐bonds	170.	The	formation	of	agglomerates	
originates	 from	 the	 pursuit	 of	 a	 state	 with	 a	 lower	 free	 surface	 energy	 and	 is	 strongly	
promoted	by	the	hydrophobic	nature	of	most	NP	154,	170.	Thus,	agglomeration	occurs	in	media	
when	attractive	forces	overpower	the	electrostatic	or	steric	repulsion	between	NP	171.		
Several	NP‐	and	medium‐related	 factors	have	been	shown	to	 influence	NP	agglomeration.	
Parameters	 in	 the	 first	 category	 are	 NP	 surface	 charge,	 size	 and	 shape.	 Brown	 et	 al.	 for	
example	found	that	nanorods	and	–fibres	agglomerate	more	easily	than	spheres	and	Limbach	
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et	 al.	 saw	 a	 higher	 agglomeration	 rate	 for	 smaller	 NP	 in	 comparison	 to	 their	 larger	
counterparts	at	similar	mass	doses,	which	was	explained	by	the	higher	number	density	172,	
173.	This	is	of	course	also	related	to	the	concentration,	which	is	another	important	factor	as	it	
is	known	that	NP	tend	to	agglomerate	at	higher	concentrations	116.	Allouni	et	al.	have	put	pH	
forward	as	one	of	 the	medium‐related	parameters	 influencing	NP	agglomeration	41.	Other	
parameters	 such	 as	 salt	 composition,	 ion	 concentration	 and	 ionic	 strength	 were	 also	
mentioned	by	a	number	of	groups	41,	171,	174.	Albanese	et	al.	have	furthermore	introduced	the	
presence	of	proteins,	in	particular	serum	proteins,	as	a	very	important	factor	171.	Its	effect	on	
NP	agglomeration	is	however	not	yet	fully	understood	as	several	groups	found	conflicting	
data	on	the	subject,	showing	either	less	or	more	agglomeration	in	media	containing	serum	
175,	176.	Still,	it	can	be	concluded	that	NP	agglomeration	can	either	be	promoted	or	mitigated	
depending	on	the	medium	composition	176.		
Since	the	majority	of	the	NP	are	unstable	in	biological	fluids,	agglomeration	is	believed	to	be	
inevitable	in	vivo	171.	Consequently	it	is	crucial	to	take	the	influence	of	NP	agglomeration	on	
diffusion	and	sedimentation	and	subsequently	on	NP	uptake	and	toxicity	into	account	when	
evaluating	nanotoxicity	in	vivo	as	well	as	in	vitro.	Certainly	since	Albanese	et	al.	observed	that	
aggregates	show	altered	kinetics	in	comparison	to	their	single	NP	counterparts	with	the	same	
size	171.	It	is	therefore	crucial	to	evaluate	NP	agglomeration	in	the	medium	in	which	the	NP	
will	 be	 added	 to	 the	 cells.	Dynamic	 light	 scattering	 (DLS)	 is	 a	 successful	 technique	but	 is	
limited	to	samples	in	simple	or	diluted	media	as	other	light	scattering	components,	such	as	
serum	 proteins,	 can	 interfere	 with	 the	 measurements	 177.	 It	 would	 however	 be	 more	
convenient	 if	 NP	 size	 and	 agglomeration	 could	 be	 studied	 in	 undiluted	 biological	 fluids.	
Therefore	 Braeckmans	 et	 al.	 developed	 a	 novel	 promising	method,	 combining	maximum	
entropy	analysis	and	fluorescent	single	particle	tracking	(fSPT),	which	allows	the	accurate	
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and	precise	determination	of	the	size	distribution	of	fluorescent	NP	in	undiluted	biological	
fluids	177.	
This	section	will	provide	an	overview	of	studies	evaluating	the	influence	of	NP	sedimentation	
on	 uptake	 and	 toxicity	 and	 innovative	 setups	 to	 avoid	 the	 effect	 of	 sedimentation	 when	
assessing	NP	effects	on	cells.			
	
	 4.1.	Effect	of	nanoparticle	agglomeration	and	sedimentation	on	cellular	uptake	
Since	agglomeration	influences	the	size,	surface	area	and	number/volume	dose,	which	are	all	
factors	known	to	affect	NP	uptake,	it	was	expected	that	agglomeration	influences	NP	uptake.	
Limbach	et	al.	therefore	compared	the	uptake	of	20‐50	nm	diameter	single	CeO2NP	and	250‐
400	 nm	 diameter	 agglomerates	 in	 a	 human	 long‐lived	 fibroblast	 cell	 line	 (MRC‐9).	 They	
observed	a	higher	uptake	 for	 the	agglomerates	as	 they	reached	 the	 cells	more	 rapidly	by	
sedimentation	than	single	NP,	whose	transport	rate	was	limited	by	diffusion	173.	Brown	et	al.	
however	observed	a	decrease	in	uptake	when	the	agglomerate’s	size	is	similar	to,	or	larger	
than	the	cell	itself	due	to	physical	restrictions	to	the	uptake	processes	172.		This	is	in	line	with	
observations	 from	 Drescher	 et	 al.	 who	 found	 higher	 uptake	 for	 the	 single	 NP	 and	 small	
agglomerates	 in	 comparison	 to	 their	 larger	 counterparts	 in	 3T3	 fibroblasts	 175.	 These	
observations	 fit	 the	 assumption	 that	 larger	 aggregates	do	not	 enter	 the	 cell	 via	 the	 same	
mechanism	as	single	NP	or	small	agglomerates	since	most	common	endocytosis	routes	like	
clathrin‐	 or	 caveolin‐mediated	 endocytosis	 are	 limited	 to	 the	 uptake	 of	 materials	 with	
dimensions	 of	maximally	 80	 nm	 175.	 Albanese	 et	al.	 furthermore	 showed	 that	 the	 uptake	
mechanism	not	only	depends	on	NP	size	but	is	also	cell	type‐dependent.	Since	they	observed	
a	25%	reduction	in	uptake	for	AuNP	agglomerates	in	HeLa	cells	and	A549	cells	but	a	2‐fold	
increase	for	the	largest	agglomerates	in	a	human	breast	cancer	cell	line	(MDA‐MB435)	171.	
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Finally	 Lankoff	 et	 al.	 observed	 differential	 uptake	 of	 single	 AgNP,	 TiO2NP	 and	 their	
agglomerates	in	HepG2,	A549	and	THP‐1	cells,	adding	NP	type‐dependency	to	the	picture	147.		
From	 the	 available	 (conflicting)	 data	 it	 cannot	 be	 concluded	whether	 single	 NP	 or	 small	
agglomerates	are	taken	up	to	a	higher	or	lesser	extent	by	the	cells.	Reviewing	these	data,	we	
do	hypothesize	that	following	factors	are	equally	important;	(i)	the	extent	of	agglomeration,	
(ii)	 the	 size	 of	 the	 agglomerates	 and	 (iii)	 the	 cellular	 uptake	 mechanism.	 The	 extent	 of	
agglomeration	 and	 the	 size	 of	 the	 agglomerates	 will	 not	 only	 determine	 the	 rate	 of	
sedimentation,	and	hereby	the	rate	of	NP	transport	 towards	the	cells,	but	also	 the	way	 in	
which	the	cells	will	handle	these	materials.	Non‐specialized	cells	will	typically	prefer	smaller	
NPs	 while	 cells	 capable	 of	 ingesting	 larger	 materials	 will	 take	 up	 higher	 levels	 of	
agglomerates.	Additional	influencing	factors	are	the	cell	type	and	type	of	NP	being	tested.	As	
such,	it	is	clear	that	agglomeration	and	sedimentation	have	an	influence	on	NP	uptake	that	
cannot	be	neglected.		
	
	 4.2.	Effect	of	nanoparticle	agglomeration	and	sedimentation	on	toxicity	
Logically,	when	NP	uptake	is	influenced	by	agglomeration	and	sedimentation,	NP	cytotoxicity	
might	 also	 be	 affected.	 Therefore	 Kirchner	 et	 al.	 compared	 toxicity	 for	 different	
concentrations	of	MPA‐	and	PEG‐coated	QD	in	MDA‐MB435	cells.	At	higher	concentrations	
both	NP	types	agglomerated,	precipitated	and	caused	injury,	with	the	PEG‐coated	NP	causing	
more	severe	cell	damage	37.	Wick	et	al.	also	found	agglomeration	to	increase	particle	toxicity	
as	CNT	agglomerates	were	more	toxic	to	MSTO‐211H	cells	than	asbestos	fibres	and	single	
CNT	178.	 In	contrast,	 some	studies	show	that	cytotoxicity	 is	 reduced	 for	agglomerated	NP,	
which	is	possibly	due	to	the	fact	that	smaller	entities	are	in	general	taken	up	more	avidly	by	
non‐specialized	 cells	 and	 are	more	 able	 to	 reach	 intracellular	 structures	 such	 as	 the	 cell	
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nucleus	or	mitochondria,	which	are	less	accessible	to	larger	particles	or	aggregates.	172,	179,	
180.	 Yoon	 et	 al.	 further	 hypothesized	 that	 adherent	 cells	 might	 be	 more	 affected	 by	 NP	
deposition	through	sedimentation	than	cells	in	suspension	and	therefore	compared	Al2O3NP	
and	agglomerate	toxicity	in	floating	cells	(THP‐1)	and	three	adherent	cell	lines	(A549,	293T	
and	J774A‐1:	a	mouse	macrophage	cancer	cell	line).	THP‐1,	A549	and	293T	cell	lines	showed	
toxicity,	but	only	A549	and	293T	cell	lines	showed	a	time	dependent	toxicity	that	could	be	
related	to	sedimentation	of	the	agglomerates,	which	confirmed	their	hypothesis	181.		
These	data	clearly	show	the	influence	of	NP	sedimentation	on	nanotoxicity	and	indicate	that	
it	can	result	in	either	underestimated	or	exaggerated	toxicity	estimations.	Therefore,	in	order	
to	reduce	the	in	vitro‐in	vivo	gap,	there	is	a	huge	need	for	novel	model	systems	in	which	the	
effect	of	NP	sedimentation	can	be	avoided	and	will	hereby	provide	toxicity	results	that	are	
more	relevant	to	the	applied	dose	of	the	NPs	rather	than	reaching	unrealistically	high	cell	
exposure	levels	due	to	NP	sedimentation.		
 
	 4.3.	New	model	systems	to	minimize	sedimentation	effects	
Following	 on	 from	 the	 sections	 above,	 it	 is	 clear	 that	 sedimentation	 is	 one	 of	 the	major	
shortcomings	to	classical	2D	cultures.	Since	sedimentation	is	not	observed	in	vivo	and	was	
demonstrated	to	affect	nanotoxicity	in	vitro,	several	groups	have	tried	to	develop	novel	model	
systems	 such	 as	 inverted	 cultures,	 flow	 models	 and	 microfluidic	 systems	 in	 which	 the	
influence	of	sedimentation	can	be	reduced	or	even	completely	avoided.		
	
a.	Inverted	models	
Cho	et	al.	evaluated	the	influence	of	sedimentation	on	uptake	of	Au	nanospheres,	‐cages	and	
‐rods	in	human	breast	cancer	cells	(SK‐BR‐3)	cultivated	in	an	inverted	cell	model.	This	is	an	
elegant	and	straightforward	cell	model	in	which	sedimentation	itself	is	not	avoided	but	it	will	
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not	 result	 in	 increased	 cellular	 exposure	 levels	 for	 cells	 that	 are	 cultured	 in	 the	 inverted	
configuration.	 The	 authors	 observed	 a	 much	 more	 avid	 uptake	 of	 NP	 in	 classical	 cell	
cultures(cells	at	 the	bottom)	 in	comparison	to	cells	cultured	 in	the	 inverted	configuration	
(cells	grown	on	an	insert,	at	the	top	of	the	medium,	facing	downwards)	(Figure	5).	However,	
no	variations	were	observed	in	toxicity,	as	cell	viability	remained	approximately	90%	of	the	
control	values	in	all	conditions	tested,	but	this	may	be	due	to	the	type	of	material	and	the	
limited	concentration‐range	that	was	tested	in	this	study.	The	differential	uptake	in	upright	
or	 inverted	 configuration	 depended	 on	 the	 physical	 properties	 of	 the	 NP	 and	 was	 most	
distinct	for	NP	with	a	greatest	propensity	to	sediment,	underscoring	the	necessity	to	avoid	
the	influence	of	sedimentation	35.		
	
	
Figure	5:	Differential	uptake	of	a,	15‐nm	nanospheres	(120	pM);	b,	54‐nm	nanospheres	(20	pM);	c,	100‐
nm	nanospheres	(2.8	pM);	d,	62‐nm	nanocages	(20	pM);	e,	118‐nm	nanocages	(2.6	pM);	and	f,	nanorods	
(20	pM)	in	the	upright	and	inverted	configuration.	
	
	 b.	Flow	and	microfluidic	models	
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More	 complicated	models	 are	 flow	or	microfluidic	 systems	where	 gravitational	 setting	 is	
impeded	or	even	completely	avoided	unlike	for	the	 inverted	model.	The	applied	flow	also	
assists	in	acquiring	a	more	homogeneous	NP	distribution	and	is	believed	to	alter	the	cell‐NP	
contact	time	36,	214.	An	additional	advantage	to	applying	a	flow	is	the	continuous	renewal	of	
medium,	which	ensures	a	sustained	supply	of	nutrients	and	a	constant	pH	36.		
It	is	expected	that	NP	uptake	might	significantly	vary	under	flow	conditions	in	comparison	to	
static	conditions	36,	182.	These	variations	may	also	be	contributed	to	altered	cell	morphology	
and	 function	under	 the	applied	shear	stress	(SS).	 It	 is	 for	 instance	known	that	SS	 induces	
elongation	of	endothelial	cells	in	direction	of	the	flow	and	the	formation	of	actin	stress	fibres	
to	protect	the	cells	from	hemodynamic	damage	in	vitro	as	well	as	in	vivo	183,	184.	Samuel	et	al.	
furthermore	 found	the	actin	network	to	be	more	dense	around	the	nucleus	and	observed	
membrane	blebbing	under	 flow	 conditions,	where	 cells	 under	 static	 conditions	 showed	a	
smooth	 and	 flattened	 morphology	 185.	 Flow	 can	 furthermore	 cause	 the	 activation	 of	
endothelial	cells	and	a	laminar	flow	has	been	shown	to	suppress	proliferation,	apoptosis	and	
ROS	induction	183.	Taking	these	aspects	into	account	application	of	a	flow	provides	a	more	
dynamic	and	in‐vivo‐like	model.	Therefore	several	groups	have	compared	NP	uptake	under	
flow	 and	 static	 conditions.	 Lin	 et	al.	 for	 instance	 found	 a	 higher	 uptake	 of	 functionalised	
polystyrene	NP	in	activated	human	aortic	endothelial	cells	(HAEC)	in	the	classical	2D	setup	
than	under	 flow	conditions	 186.	Bhowmick	et	al.	 confirmed	 these	results	as	 they	observed	
30%	higher	uptake	under	static	condition	for	targeted	NP	in	activated	HUVECs	and	EAhy296	
cells	(a	human	umbilical	vein	long	lived	cell	line)	184.	On	the	contrary	Samuel	et	al.	did	not	
observe	uptake	in	the	static	configuration	in	cells	from	a	HUVEC	cell	line	(CRL‐1730)	whereas	
these	cells	did	take	up	untargeted	NP	under	flow	conditions	185.		
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Some	groups	have	also	investigated	whether	different	levels	of	SS	have	an	influence	on	NP	
uptake.	For	example	Farokhzad	et	al.	looked	into	the	uptake	of	targeted	NP	by	two	human	
prostate	cancer	cell	lines	(LNCaP	and	PC3)	under	three	different	SS	conditions	(0.28,	1.1	and	
4.5	 dyn/cm2)	 and	 observed	 the	 highest	 adherence	 and	 uptake	 under	 the	 lowest	 SS	 187.	
Kusunose	 et	 al.	 found	 similar	 results	 for	 VCAM‐1	 targeted	 liposomes	 in	 TNFα‐activated	
HUVECs	where	the	targeting	efficiency	was	the	highest	under	the	lowest	shear	condition	188.	
Bhowmick	et	al.	observed	the	same	effect	for	targeted	NP	in	vivo	in	mice	and	attributed	this	
effect	to	impaired	endocytosis	by	the	augmented	SS	due	to	of	an	increased	stiffness	of	the	
cytoskeleton	184.		
Samuel	et	al.	furthermore	looked	into	the	influence	of	the	activation	of	endothelial	cells	on	
NP	uptake	and	observed	none	for	untargeted	NP	in	CRL‐1730	cells	185.	Lin	et	al.	did	however	
find	 higher	 NP	 uptake	 levels	 in	 histamine‐activated	 HAECs	 for	 P‐selectin	 targeted	
polystyrene	NP	186.	Bhowmick	et	al.	once	more	supported	these	findings	as	they	observed	
higher	uptake	of	functionalized	NP	in	activated	HUVECs	and	EAhy296	cells	184.	These	findings	
implicate	that	NP	uptake	under	flow	conditions	does	not	only	depend	on	the	level	of	SS	but	
also	on	the	activation	status	of	endothelial	cells	and	on	whether	NP	are	functionalized	or	not.		
As	uptake	is	significantly	altered	under	flow	conditions	it	is	expected	that	the	same	will	be	
true	for	nanotoxicity.	On	the	one	hand	Mahto	et	al.	observed	significantly	higher	levels	of	QD	
toxicity	 in	 3T3	 fibroblasts	 in	 static	 configuration:	 cells	 in	 static	 condition	 showed	
approximately	30%	cell	viability	whereas	the	percentage	of	living	cells	under	SS	remained	
75%	and	a	significantly	higher	number	of	deformed	and	detached	cells	was	found	under	the	
static	condition	36.	Kim	et	al.	on	the	other	hand	found	significant	levels	of	toxicity	under	high	
SS	(3.3	and	6.6	dyn/cm2)	whereas	HUVECs	under	static	conditions	or	low	SS	(0.5	dyn/cm2)	
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did	not	show	significant	toxicity	after	2h	exposure	to	unmodified	SiO2NP.	They	accounted	
this	difference	to	the	possible	activation	of	the	HUVECs	under	higher	SS	182.		
It	is	clear	from	these	data	that	toxicity	levels	found	in	classical	2D	monocultures	are	either	
exaggerated	or	underestimated	in	comparison	to	levels	obtained	from	in	vitro	experiments	
where	(the	effect	of)	sedimentation	is	avoided.	When	NP	toxicity	is	evaluated	in	a	flow	system	
and	 an	 extra	 level	 of	 complexity	 is	 added	 as	 the	 induced	 SS	 influences	 cell	 morphology,	
stiffness,	the	endocytotic	pathway	and	can	activate	HUVECs	which	are	all	factors	influencing	
NP	uptake	and	toxicity.	It	is	observed	that	functionalised	NP	are	taken	up	more	avidly	under	
higher	SS	conditions,	which	may	be	explained	by	the	activation	of	the	endothelial	cells	in	this	
condition,	while	 non	 targeted	NP	 show	higher	 uptake	under	 static	 conditions.	Results	 on	
nanotoxicity	 are	 on	 the	 contrary	 conflicting	 so	no	 firm	 conclusions	 can	be	drawn	on	 this	
subject	yet.	But,	as	toxicity	levels	measured	in	these	novel	model	systems	significantly	differ	
from	those	obtained	from	classical	static	2D	monocultures	and	the	former	are	believed	to	be	
more	 in	 vivo	 like,	 these	models	 should	 be	 optimised	 and	 their	 use	 should	 be	 promoted.	
Certainly	since	many	of	the	apparent	discrepancies	encountered	in	the	available	data	can	be	
attributed	to	the	 level	of	sedimentation	of	the	NP.	Therefore	the	 level	of	sedimentation	in	
complex	biological	media	should	also	be	analysed	for	which	the	described	models	are	also	
good	tools.		
	
5. The	effect	of	cell	communication	
In	most	 in	vitro	experiments	a	single	cell	type,	mostly	the	parenchymal	cell	type,	from	the	
target	organ	 is	used	 in	an	attempt	to	predict	 the	 in	vivo	effect	38.	These	monocultures	are	
static	models	with	a	very	limited	level	of	complexity	while	the	in	vivo	environment	is	complex	
and	dynamic	31,	182.	As	organs	consist	of	multiple	types	of	differentiated	cells,	all	with	their	
42	
	
specific	 function,	modelling	 the	 in	vivo	 response	by	only	using	a	 single	 cell	 type	 is	nearly	
impossible	189.	This	is	believed	to	be	a	major	factor	contributing	to	the	large	discrepancies	
that	are	often	found	between	in	vitro	and	in	vivo	data.		
An	 important	shortcoming	of	the	monoculture	model,	partially	causing	the	 in	vitro‐in	vivo	
gap,	is	the	lack	of	intercellular	communication.	This	crosstalk	between	different	cell	types	is	
known	to	be	vital	in	sustaining	homeostasis	at	both	the	cellular	and	the	organ	level	and	in	
complicated	processes	requiring	the	interaction	of	multiple	cell	types	such	as	the	processing	
of	 xenobiotics,	 inflammation	 and	 immune	 responses.	 It	 is	 therefore	 a	major	 challenge	 to	
accurately	model	these	processes	in	vitro.	Consequently,	several	processes	like	inflammation	
or	 immune	 responses	 cannot	 be	 accurately	modelled	 in	monocultures	 190,	 191.	 In	 order	 to	
overcome	 this	 shortcoming	 several	 groups	 have	 focussed	 on	 establishing	 co‐cultures	 to	
bridge	the	in	vitro‐in	vivo	gap.	Multiple	types	of	co‐cultures	can	be	set	up	as	two	or	more	cell	
types	can	be	combined	and	cells	can	be	cultured	either	in	direct	contact	or	be	separated	by	
culture	inserts.	Kasper	et	al.	observed	that	cells	co‐cultured	on	culture	inserts	show	a	more	
differentiated	 phenotype	 and	 are	 polarised,	 implying	 that	 the	 cells	 have	 an	 apical	 and	
basolateral	membrane	with	a	distinct	composition	192.	Furthermore	co‐cultured	cells	often	
display	tight	and	adherent	junctions	193.	Thus,	these	models	more	closely	mimic	the	in	vivo	
environment	and	are	therefore	assumed	to	have	a	higher	predictive	power.	Since	it	was	also	
expected	that	NP	uptake	and	NP	induced	injury	would	significantly	differ	in	co‐cultures	in	
comparison	to	monocultures,	several	groups	evaluated	NP	uptake	and	toxicity	in	these	novel	
model	systems	that	were	initially	developed	for	hazard	assessment	of	chemical	substances.	
An	overview	of	these	data	is	provided	in	this	section.		
	
5.1. Effect	of	intercellular	communication	on	NP	uptake	
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Since	it	is	well	known	that	the	majority	of	NP	are	rapidly	taken	up	by	the	reticulo‐endothelial	
system	after	intravenous	administration	of	the	NP	in	vivo,	a	number	of	groups	investigated	
whether	 the	 same	 trend	 could	 be	 observed	 in	 vitro	 in	 co‐cultures	 of	 epithelial	 and	
phagocytotic	cells.	For	instance	Rothen‐Rutishauer	et	al.	evaluated	uptake	of	polystyrene,	Au	
and	TiO2NP	in	a	co‐culture	consisting	of	A549	cells,	human	monocyte	derived	macrophages	
(MDM)	and	human	monocyte	derived	dendritic	 cells	 (MDDC).	They	observed	preferential	
uptake	 of	 all	NP	 in	MDM	and	 the	 least	 uptake	 in	A549	 cells	 (Figure	 6).	 Compared	 to	 the	
MDDCs	 uptake	 in	 MDM	 was	 twice	 as	 high,	 which	 was	 explained	 by	 the	 2‐fold	 greater	
phagocytotic	capacity	of	the	latter	194.	Pinkernelle	et	al.	 looked	into	IONP	uptake	in	mixed	
cultures	of	rat	primary	neuronal	cells,	a	spinal	chord/peripheral	nerve	graft	co‐culture	and	a	
Schwann	cell/fibroblast	co‐culture.	IONP	were	evenly	taken	up	in	both	cell	types	in	the	latter	
co‐culture,	while	in	both	the	mixed	culture	of	primary	cells	and	the	spinal	chord/peripheral	
nerve	 graft	 co‐culture,	 the	 highest	 uptake	 was	 observed	 in	 the	 microglia,	 which	 are	 the	
resident	 macrophages	 of	 the	 CNS	 195.	 Since	 both	 studies	 show	 a	 preferential	 uptake	 in	
macrophages	 due	 to	 their	 phagocytotic	 capacity,	 this	 effect	 should	 be	 taken	 into	 account	
when	 evaluating	 NP	 hazard	 on	 epithelial	 or	 endothelial	 cells	 as	 NP	 uptake	 can	 be	
overestimated	in	monocultures	leading	to	exaggerated	NP	toxicity	outcomes.		
Kasper	et	al.	compared	silica	NP	uptake	in	H441	cells	in	a	monoculture	and	H441/ISO‐HAS‐
1	co‐culture	with	H441	being	a	human	lung	adenocarcinoma	epithelial	cell	line	and	ISO‐HAS‐
1	a	human	microvascular	endothelial	cancer	cell	line.	For	the	H441	cells,	a	higher	NP	uptake	
was	observed	in	the	monoculture	experiments,	which	was	explained	by	the	fact	that	in	co‐
culture	H441	 cells	 are	 further	 differentiated,	 polarised	 and	 show	a	more	barrier‐forming	
phenotype,	impeding	NP	uptake	192.		
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It	 can	be	concluded	 from	these	data	 that	NP	uptake	 is	 significantly	altered	 in	co‐cultures.	
When	macrophages	are	added	to	the	co‐culture	they	will	preferentially	take	up	the	NP.	This	
might	have	a	significant	influence	on	the	induced	toxicity	as	the	NP	dose	will	not	be	equal	in	
all	cell	types,	but	is	likely	to	be	higher	in	the	macrophages	and	lower	for	other	cell	types	in	
comparison	to	the	intracellular	dose	in	monocultures.	Additionally,	when	macrophages	take	
up	high	 levels	of	 these	NP,	 this	may	result	 in	strong	reactions	 that	naturally	occur	within	
these	cells	when	dealing	with	pathogens,	including	the	generation	of	a	strong	oxidative	burst	
or	 secretion	of	pro‐inflammatory	 cytokines,	which	may	 then	affect	 any	 surrounding	 cells.	
This	 secondary	 damage,	 induced	 by	 the	 macrophages,	 would	 never	 be	 picked	 up	 in	
monoculture	 experiments	 underscoring	 the	 importance	 of	 performing	 co‐culture	
experiments.	
	
Figure	6:	Preferential	uptake	of	fluorescent	polystyrene	beads	in	human	monocyte	derived	macrophages	
(MDM)	in	co‐culture	with	A549	cells	(EP)	and	human	monocyte	derived	dendritic	cells	(MDDC).	
	
5.2. Effect	of	intercellular	communication	on	NP	toxicity	
It	was	hypothesized	that	intercellular	communication	in	co‐cultures	could	significantly	alter	
NP	toxicity,	certainly	since	it	was	shown	that	NP	are	not	taken	up	evenly	in	different	cell	types	
when	phagocytotic	cells	are	included	in	the	co‐culture.	As	such,	activation	of	these	cells	and	
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the	release	of	pro‐inflammatory	cytokines	may	have	secondary	effects	on	other	cell	types,	the	
effect	of	which	can	only	be	studied	using	co‐culture	models.		
Since	the	lung	is	expected	to	be	one	of	the	major	target	organs	of	NP	toxicity	via	the	inhalation	
of	airborne	NP,	most	studies	are	performed	on	co‐cultures	representing	alveolar	tissue.	For	
instance	Wottrich	et	al.	compared	the	cytotoxicity	induced	by	particulate	matter	(PM10)	in	
A549	and	differentiated	THP‐1	monocultures	and	co‐culture.	They	observed	an	 increased	
cytokine	release	by	the	cells	in	co‐culture	in	comparison	to	both	monocultures	196.	Ishii	et	al.	
performed	a	similar	study	exposing	a	co‐culture	of	human	alveolar	macrophages	and	human	
bronchial	epithelial	cells	and	the	corresponding	monocultures	to	PM10	and	also	found	the	
cells	in	co‐culture	to	secrete	more	cytokines	than	the	sum	of	the	cytokine	secretion	in	the	
monocultures	197.	When	Kim	et	al.	evaluated	the	potential	of	8	metal	NP	to	induce	apoptosis	
in	 a	 RAW264.7/MLE12	 (murine	 alveolar	 long‐lived	 cell	 line)	 co‐culture	 and	 both	
monocultures	they	found	the	co‐culture	to	be	more	susceptible	to	apoptotic	damage,	which	
was	explained	by	 the	 increased	TNFα	 release	by	 the	RAW264.7	 cells	 and	 therefore	 to	 the	
intercellular	communication	198.		
Another	popular	combination	consists	of	alveolar	epithelial	and	microvascular	endothelial	
cells	 to	mimic	 the	 air‐blood‐barrier.	 Culture	 inserts	 separate	 the	 two	 cell	 types	 and	 only	
epithelial	cells	(representing	the	apical	membrane)	are	exposed	to	NP.	Using	this	model,	the	
potential	 to	 activate	 endothelial	 cells,	 which	 can	 subsequently	 induce	 systemic	 effects,	
through	intercellular	communication	can	be	evaluated.	Kasper	et	al.	evaluated	the	toxicity	
induced	 by	 35	 nm	 diameter	 SiO2NP	 in	 the	 H441/ISO‐HAS‐1	 co‐culture	 and	 H441	
monoculture.	They	found	the	co‐culture	to	be	more	resilient	to	nanotoxicity	in	terms	of	acute	
toxicity	 but	 it	 showed	 an	 increased	 inflammatory	 response	when	 compared	 to	 the	H441	
monoculture	193.	In	a	follow‐up	study	similar	results	were	obtained	when	30	and	48.1	nm	
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diameter	SiO2NP	were	tested	under	the	same	circumstances	192.	Bengali	et	al.	made	similar	
observations	when	evaluating	the	effect	of	PM10,	CuO	and	TiO2NP	on	a	H441/HPMEC‐ST1‐6R	
(human	 pulmonary	 microvascular	 endothelial	 long‐lived	 cell	 line)	 co‐culture	 as	 apical	
exposure	caused	significant	modulation	of	pro‐inflammatory	modulators	 in	both	cell	 lines	
without	the	endothelial	cell	being	in	direct	contact	with	the	NP	199.	Ramos‐Godinez	et	al.	on	
the	contrary	did	not	find	any	changes	in	cytokine	release	for	a	A549/HUVEC	co‐culture	after	
TiO2NP	exposure.	HUVECs	from	the	co‐culture	did	however	show	a	significant	 increase	 in	
adhesion	molecules,	 a	3	 to	4‐fold	 increase	 in	monocyte	adhesion	and	a	2‐fold	 increase	 in	
nitric	 oxide	 (NO)	 production.	 These	 results	 were	 comparable	 to	 cells	 from	 the	 HUVEC	
monoculture,	which	were	directly	exposed	to	the	NP,	 implying	that	endothelial	cells	were	
activated	via	intercellular	communication	in	co‐cultures	200.	In	none	of	these	studies	NP	were	
found	to	cross	the	culture	insert,	possibly	due	to	the	barrier	formed	by	the	epithelial	cells	or	
agglomeration	of	 the	NP.	This	supports	 the	hypothesis	 that	endothelial	cells	are	activated	
through	intercellular	communication	after	exposure	of	epithelial	cells	to	NP.		
Since	it	was	shown	that	macrophages	can	have	an	effect	on	the	toxicity	observed	in	epithelial	
cells,	 several	 groups	 investigated	 whether	 the	 activation	 status	 of	 macrophages	 has	 an	
influence.	 Soma	 et	 al.	 compared	 the	 effect	 of	 doxorubicin	 loaded	 PACA	 NP	 on	 a	
M5076/J774.A1	(mouse	reticular	cell	sarcoma	cell	line/mouse	monocyte‐macrophage	long‐
lived	cell	 line)	co‐culture,	with	the	latter	cell	 line	either	being	unactivated	or	activated	via	
IFN‐γ	treatment.	It	was	observed	that	non‐activated	macrophages	acted	as	a	reservoir,	thus	
performing	a	protective	function	while	activated	macrophages	elicited	secondary	toxicity	in	
M5076	cells	trough	exocytosis	of	the	drug	and	excretion	of	TNFα	and	NO	201.	Al‐Hallak	et	al.	
confirmed	these	findings	as	they	obtained	similar	results	for	doxorubicin	loaded	NP	in	the	
MS‐H/H460	co‐culture	(murine	alveolar	macrophages/human	lung	carcinoma	cell	line)	202.	
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van	Berlo	et	al.	furthermore	found	that	the	protective	or	aggravating	effect	on	NP	toxicity	also	
depends	on	the	combination	of	cell	types	as	he	evaluated	DQ12	toxicity	in	co‐cultures	of	A549	
cells	 combined	 with	 either	 C57BL/6J	 mice	 neutrophils	 or	 C57BL/6J	 mice	 macrophages	
without	 culture	 inserts.	 The	 macrophages	 protected	 A549	 cells	 against	 oxidative	 DNA	
damage	whereas	the	neutrophils	aggravated	the	effect	203.		
Some	 groups	 added	 one	 or	 more	 additional	 cell	 types	 to	 create	 an	 even	 more	 complex	
environment.	 For	 example	 Alfaro‐Moreno	 et	 al.	 evaluated	 the	 effects	 of	 PM10	 in	 several	
combinations	 of	 cell	 lines:	 A549/HMC‐1,	 THP‐1/HMC‐1,	 A549/THP‐1/HMC‐1	 and	
A549/THP‐1/HMC‐1/EAhy296.	All	cultures	had	a	distinct	cytokine	excretion	profile	with	the	
co‐culture	of	mast	cells	(HMC‐1)	and	macrophages	(THP‐1)	showing	a	synergistic	increase	in	
cytokine	excretion	 in	comparison	to	their	monocultures.	Which	 is	 interesting	as	 it	 fits	 the	
observation	that	pollution	aggravates	asthma.	They	showed	that	cytokine	production	could	
be	amplified	or	mitigated	 in	co‐culture,	which	was	explained	by	differential	expression	of	
receptors	at	the	cell	surface	depending	on	the	cell	type	or	changes	in	crosstalk	between	the	
cells	by	addition	of	an	extra	cell	type	204.	Müller	et	al.	compared	nanotoxicity	of	PM10,	SWCNT	
and	 TiO2NP	 in	 a	 co‐culture	 consisting	 of	 A549,	 MDC	 and	 MDDC	 and	 the	 corresponding	
monocultures.	 They	 found	 that	 the	 interaction	 between	 the	 cells	 modulated	 the	 total	
antioxidant	 capacity	 and	 the	 cytokine	 excretion	 205.	 It	 can	 therefore	 be	 stated	 that	 the	
interplay	between	different	cell	types	significantly	modulates	the	oxidative	stress	levels	and	
the	inflammatory	response,	which	are	both	known	to	be	affected	by	NP	exposure.		
To	summarize	we	can	conclude	from	these	data	that	cells	react	differently	to	NP	exposure	
when	they	are	cultured	in	mono‐	or	co‐cultures.	Apart	from	some	exceptions,	co‐cultures	are	
mostly	found	to	be	more	resilient	to	acute	toxicity	but	show	a	significant	increase	in	cytokine	
release,	indicative	of	an	inflammatory	or	immune	response.	The	effect	does	however	depend	
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on	the	combination	of	cell	types	that	were	co‐cultured	and	can	be	altered	by	addition	of	an	
extra	cell	type.	Furthermore,	it	has	been	shown	that	epithelial	cells	are	capable	of	activating	
endothelial	cells	through	intercellular	communication	after	NP	exposure.	The	activation	of	
macrophages	 also	 appeared	 to	 be	 important	 as	 activated	 macrophages	 cause	 secondary	
toxicity	whereas	non‐activated	macrophages	have	a	protective	reservoir	function.	These	data	
clearly	indicate	the	importance	of	cell‐cell	communication	and	the	differences	in	responses	
to	NP	exposure	for	cells	in	co‐cultures.	This	is	very	important	for	NP	hazard	assessment	since	
these	models	are	more	in	vivo	like	and	therefore	more	relevant	and	likely	to	have	a	higher	
predictive	power.		
	
6. The	effect	of	a	3D	environment	
A	final	major	shortcoming	to	classical	2D	monocultures	that	will	be	discussed	in	this	review	
is	 the	 loss	 of	 the	 specific	 3D	 tissue	 architecture	 and	 associated	with	 this,	 the	 loss	 of	 cell	
polarisation.	 2D	 cultures	 therefore	 generally	 fail	 to	 reconstitute	 the	 in	 vivo	
microenvironment	as	they	offer	a	reductionist	approach	with	spatial	limitations	leading	to	
expression	of	a	different	cellular	phenotype	and	consequently	to	the	vast	in	vitro‐in	vivo	gap	
206.	Not	only	cellular	organisation	and	polarisation	are	lost	in	classical	2D	monocultures,	cells	
also	fail	to	produce	an	in	vivo‐like	extracellular	matrix	(ECM).	Cells	are	still	able	to	produce	
and	secrete	ECM	proteins	in	a	2D	environment	but	the	extent	of	ECM	production	is	altered	
and	the	barrier	formed	is	less	dense	and	incomplete	in	comparison	to	the	in	vivo	ECM	207.	This	
ECM	is	a	very	important	factor	as	it	is	a	natural	barrier	with	small	pores	and	therefore	limits	
NP	diffusion	into	a	tissue	208.	It	is	furthermore	a	key	regulator	in	homeostasis	and	phenotype	
expression.	 Cells	 cultured	 in	 a	 3D	 setup	 are	 consequently	 able	 to	 acquire	 tissue‐like	
organization	and	differentiation,	in	part	via	the	ECM	stimulating	the	cells,	to	levels	that	have	
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thus	 far	been	 impossible	 to	reach	 in	a	classical	2D	setting	206.	Since	cells	are	more	 tightly	
packed	in	the	3D	setup,	these	models	also	promote	cell‐cell	and	cell‐matrix	communication,	
necessary	for	maintaining	homeostasis.	In	turn,	the	enhanced	communication	influences	a	
number	of	important	cellular	functions	such	as	migration,	invasion,	proliferation,	apoptosis	
and	 differentiation	 209.	 	 It	 was,	 for	 example,	 shown	 by	 Kuo	 et	 al.	 that	 the	 epithelial‐
mesenchymal‐transition,	 which	 is	 a	 hallmark	 in	 the	 metastatic	 process,	 is	 promoted	 for	
several	cancer	cell	lines	when	they	are	cultured	as	spheres	210.	Thus,	it	can	be	concluded	that	
the	cultivation	conditions	have	a	major	influence	on	the	cellular	phenotype	and	function	and	
that	cellular	responses	following	NP	exposure	are	therefore	likely	to	be	drastically	altered	in	
a	3D	model	when	compared	to	a	conventional	monolayer	207.		
A	number	of	3D	systems	have	been	developed	of	which	the	multicellular	spheroid	models,	
mimicking	solid	tumours,	are	most	widely	used.	Another	approach	is	the	use	of	natural	or	
synthetic	hydrogels	as	a	scaffold	in	which	cells	can	be	seeded	211.	Hydrogel‐based	scaffolds	
are	 however	 likely	 to	 be	 not	 very	 useful	 for	 NP	 studies	 as	 thick	 scaffolds	 will	 limit	 the	
diffusion	of	NP	towards	the	cells,	which	will	drastically	alter	the	outcome	of	any	uptake	or	
toxicity	studies.	 Initially	many	research	groups	applied	these	3D	models	 in	 in	vitro	cancer	
research	 as	 they	 tested	 multiple	 anti‐cancer	 agents	 for	 their	 anti‐proliferative	 capacity.	
Currently	these	models	are	also	being	used	to	evaluate	the	delivery	and	therapeutic	efficiency	
of	nanomedicines	and	the	toxicity	of	engineered	nanomaterials.	The	following	section	will	
provide	an	overview	on	recent	data	on	NP	uptake	and	toxicity	in	a	3D	setup.	
	
6.1. Effect	of	a	3D	environment	on	NP	uptake	
As	cells	cultured	in	spheroids	are	known	to	produce	a	more	dense	and	complex	ECM,	which	
is	a	natural	barrier	and	hampers	NP	diffusion	towards	the	cells,	several	groups	compared	NP	
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uptake	 in	 a	 2D	 and	 3D	 setting.	 For	 instance	 Mitra	 et	 al.	 found	 a	 slow	 diffusion	 and	
heterogeneous	distribution	of	anti‐cancer	drug	loaded	NP	in	Y79	(retinoblastoma)	spheres	
in	comparison	to	an	even	distribution	in	classical	monocultures	of	the	same	cells.	The	naïve	
drugs	 on	 the	 other	 hand	 were	 distributed	 homogeneously	 throughout	 the	 spheres	 212.	
Godugu	 et	 al.	 observed	 limited	 penetration	 of	 dox‐loaded	 NP	 in	 comparison	 to	 free	
doxorubicin	in	three	different	human	non	small	cell	lung	carcinoma	spheres	(H460,	A549	and	
H1650).	Consequently	NP	uptake	was	only	observed	in	cells	in	the	peripheral	layers	of	the	
spheres	209.	Biondi	et	al.	compared	the	uptake	of	dox‐loaded	NP	in	3D‐collagen	matrices	to	
2D	cultures	of	HeLa	cells	and	also	found	the	NP	transport	to	be	limited	in	a	3D	environment	
and	uptake	to	be	higher	in	cells	in	a	2D	culture	213.	Huang	et	al.	furthermore	compared	the	
uptake	of	2,	6	and	15	nm	diameter	AuNP	in	a	MCF‐7	monolayer,	spheroid	model	and	mouse	
breast	tumours	in	vivo.	In	all	experiments	the	same	trend	could	be	observed	in	that	the	2nm	
NP	were	taken	up	more	avidly	than	their	larger	counterparts.	The	spheroids	and	tumours	
showed	the	same	trends	in	tissue	penetration	as	2	and	6	nm	NP	could	penetrate	the	deeper	
regions	of	the	cell	mass,	but	15	nm	NP	were	only	found	in	the	periphery	while	all	NP	were	
evenly	distributed	in	the	monolayer	214.		
Thus,	it	is	generally	seen	that	distribution	of	the	NP	is	less	homogeneous	in	3D	cultures	when	
compared	to	the	conventional	monolayers.	Furthermore,	NP	penetration	into	a	3D	matrix	is	
hampered	by	the	ECM	and	uptake	is	consequently	often	limited	to	the	cells	in	the	peripheral	
layers	of	the	3D	culture,	especially	for	larger	NP.		
	
6.2. Effect	of	a	3D	environment	on	NP	toxicity	
Since	uptake	is	drastically	altered	in	a	3D	environment	it	was	assumed	that	the	same	would	
be	seen	for	cellular	responses	to	NP	exposure.	Therefore	several	groups	evaluated	NP	toxicity	
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simultaneously	 in	2D	and	3D	cultures.	 In	 the	context	of	 the	 initial	application	of	spheroid	
models,	Godugu	et	al.	 evaluated	 the	anti‐proliferative	 capacity	of	dox‐loaded	NP	on	 three	
different	 human	 non	 small	 cell	 lung	 carcinoma	 spheres	 (H460,	 A549	 and	 H1650)	 in	
comparison	to	the	same	cells	cultured	in	a	2D	monolayer.	They	found	significantly	altered	
toxicological	profiles	as	 IC50	values	were	elevated	5	 to	20	 times	 in	 the	3D	setup,	which	 is	
indicative	of	a	 lower	toxicity	 in	the	 latter	209.	Mitra	et	al.	confirmed	these	findings	as	they	
found	a	significantly	lower	anti‐proliferative	capacity	for	anti‐cancer	agents	enclosed	in	NP	
in	Y79	retinoblastoma	3D	cultures	in	comparison	to	both	the	naive	agents	or	the	NP	used	to	
label	the	cells	in	a	2D	setting	212.	As	mentioned	before,	this	model	was	recently	introduced	to	
nanohazard	assessment	as	to	avoid	shortcomings	from	the	classical	2D	monocultures.	For	
example	Lee	et	al.	evaluated	2.9	nm	diameter	CdTe	QD	and	3.5	nm	diameter	AuNP	toxicity	in	
HepG2	2D	and	spheroid	 cultures	and	 found	a	 substantially	 lower	 toxicity	 in	 the	 spheroid	
cultures	based	on	MTT,	LDH	and	calcein	AM	assays	and	morphological	analysis.	The	number	
of	dead	cells	was	significantly	lower	in	the	3D	setup	and	most	dead	cells	were	found	in	the	
periphery	of	the	sphere	creating	a	rugged	surface	(Figure	7).	Longer	exposure	times	induced	
more	 severe	 damage	 to	 the	 cells	 in	 periphery	 of	 the	 sphere	while	 the	 interior	 remained	
unimpaired,	while	when	the	same	incubation	conditions	were	applied	to	2D	cultures	more	
overall	cell	death	was	observed	(Figure	8).	They	attributed	these	effects	 to	 the	protective	
effect	 of	 the	 barrier	 consisting	 of	 the	 ECM	 layer	 secreted	 by	 the	 cells	 and	 the	 dead	 cells	
remaining	on	 the	exterior	of	 the	sphere,	due	 to	 the	 tight	packing	of	 the	cells,	 temporarily	
enhancing	the	efficiency	of	the	barrier	215.	Luo	et	al.	obtained	similar	results	when	evaluating	
CdSe/ZnS	QD,	IONP	and	SiNP	toxicity	in	HeLa	microspheres	as	they	found	nanotoxicity	to	be	
radial	 and	 lower	 in	 the	3D	 setup	due	 to	 the	protective	effect	 of	 the	 surrounding	 cells	 208.		
Movia	et	al.	compared	SWCNT	toxicity	in	THP‐1	2D	cultures	and	cell	aggregates	and	found	
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the	latter	not	to	be	affected	while	significant	toxicity	and	elevated	cytokine	secretion	were	
observed	in	the	conventional	monolayer	216.	On	the	contrary,	Yu	et	al.	 found	5	and	30	nm	
diameter	 IONP	 to	 cause	 more	 severe	 toxicity	 starting	 at	 lower	 doses	 to	 porcine	 aortic	
endothelial	cells	in	a	3D	alginate	matrix	than	for	cells	in	a	conventional	monolayer.	It	must	
however	be	noted	that	cells	were	unable	to	divide	once	added	to	the	matrix	while	cells	in	2D	
culture	retained	their	proliferative	capacity.	Since	toxicity	was	only	measured	after	72h	of	
exposure,	cells	 in	2D	cultures	were	likely	to	be	exposed	to	lower	doses	of	IONP	as	NP	are	
diluted	upon	cell	division.	This	protective	effect	was	likely	impeded	in	the	3D	setup,	which	
possibly	caused	the	cells	to	undergo	higher	levels	of	stress	as	they	faced	higher	doses	of	the	
IONP,	resulting	in	elevated	levels	of	toxicity	217.		
An	additional	advantage	to	3D	models	is	the	fact	that	cultivation	times	of	most	cells	can	be	
prolonged,	 enabling	 long(er)‐term	 experiments	 in	 vitro.	 For	 instance	 Hackenberg	 et	 al.	
exposed	3D	mini‐organ	cultures	of	human	nasal	mucosa	on	three	subsequent	days	to	ZnONP	
for	1h	and	did	not	find	any	acute	toxicity	or	apoptosis	but	did	observe	DNA	damage	218.	Thus,	
3D	models	can	be	applied	to	assess	cumulative	effects	while	this	is	hampered	in	2D	cultures	
as	cells	do	not	survive	longer	cultivation	periods,	dedifferentiate	or	rapidly	divide	causing	
dilution	of	the	NP	and	an	associated	dilution	of	any	possible	effects.	
It	can	be	concluded	from	these	findings	that	culturing	cells	in	a	3D	setup	has	a	major	influence	
on	 the	cellular	phenotype	and	 function	and	therefore	causes	cells	 to	react	 in	a	drastically	
different	manner	 to	NP	exposure.	Results	 from	experiments	 in	a	3D	 setup	 therefore	vary	
widely	 from	 those	obtained	 in	 their	2D	counterparts	as	most	 studies	 show	hampered	NP	
penetration	through	the	ECM	barrier	and	reduced	cellular	uptake.	Subsequently	toxicological	
profiles	are	significantly	altered,	as	toxicity	is	mostly	lower	and	limited	to	the	outer	layers	of	
the	culture.	These	3D	models	are	likely	to	have	a	higher	predictive	power,	as	they	are	a	closer	
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representation	of	the	in	vivo	environment.	Thus,	the	development	of	3D	models	is	a	recent	
milestone	 in	 bridging	 the	 in	 vitro‐in	 vivo	 gap	 and	 these	models	 are	 likely	 to	 greatly	 gain	
importance	in	the	next	few	years.		
	
Figure	7:	Confocal	images	of	live/dead‐stained	normal	E)	2D	and	G)	3D	spheroid	cultures	and	after	CdTe	
NP	exposure	in	F)	2D.and	H)	3D	spheroid	cultures.	
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Figure	 8:	 SEM	 images	 of	 2D	 and	 3D	 spheroid	 cultures	 before	 and	 after	 CdTe	NP	 exposure.	Typical	
morphology	of	A)	2D	and	D)	3D	spheroid	cultures	after	5	days	without	CdTe	NP	exposure.	Representative	
morphology	of	B)	2D	and	E)	3D	spheroid	cultures	after	12	h	of	CdTe	NP	treatment.	Morphological	change	
of	C)	2D	and	F)	3D	spheroid	cultures	after	24	h	of	CdTe	exposure.	
	
7. Conclusion	and	outlook	
The	present	review	provides	an	overview	of	several	strategies	that	have	recently	been	put	
forward	in	order	to	try	and	optimize	cell	models	for	more	robust	and	reliable	in	vitro	analysis	
of	 NP	 uptake	 and	 toxicity	 in	 advance	 of	 any	 in	 vivo	 applications.	 Where	 the	 field	 of	
nanotoxicology	is	advancing	fast,	it	is	still	lagging	behind	the	rapid	developments	in	the	field	
of	nanotechnology.	The	great	number	of	different	 types	of	materials,	each	with	 their	own	
specific	 features	 and	 the	 heavy	 impact	 of	 even	 the	 most	 miniature	 changes	 in	 a	 single	
physicochemical	parameter	of	a	NP	on	its	 interaction	with	biological	entities	make	it	very	
hard	to	thoroughly	evaluate	the	interactions	of	nanomaterials	with	cells	or	tissues.	Where	in	
vitro	 studies	 are	 now	 often	 being	 performed	 by	 many	 research	 groups	 and	 are	 being	
optimized	more	and	more	in	order	to	overcome	some	of	the	initial	hurdles,	in	vivo	studies	
remain	scarce.	The	most	used	in	vitro	model,	namely	the	classical	2D	monoculture,	is	however	
a	 very	 reductionist	 approach	were	most	of	 the	 complexity	of	 the	 in	 vivo	 situation	 is	 lost.	
Therefore,	 results	 from	 in	 vitro	 studies	 often	 did	 not	 relate	 very	 well	 with	 the	 findings	
obtained	 in	 in	vivo	 studies.	 Several	 groups	have	 subsequently	made	 substantial	 efforts	 in	
trying	 to	 optimize	 the	 current	 in	 vitro	 models	 to	 better	mimic	 the	 in	 vivo	 conditions.	 As	
described	in	the	various	sections	above,	the	use	of	 inverted	cell	cultures,	 flow	models,	co‐
cultures	 or	 3D	 cell	 cultures	 all	 have	 their	 advantages	 compared	 to	 the	 classical	 2D	
monolayers	used	for	NP	uptake	and	toxicity	studies.	
As	 the	 field	 of	 nanotechnology	 keeps	 blooming	 and	 the	 safety	 of	 nanomaterials	 remains	
questionable	as	we	are	all	being	exposed	more	and	more,	it	is	to	be	expected	that	all	these	
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models	will	gain	more	importance	as	more	robust	rapid	screening	tools.	Based	on	the	data	
obtained	with	these	models,	better	predictions	should	be	possible	as	well	as	a	better	selection	
of	materials	more	 interesting	 to	 further	 evaluate	 in	 in	 vivo	 studies.	More	 optimisation	 is	
however	needed	to	fully	exploit	the	benefits	of	these	models.	One	aspect	that	further	needs	
to	be	looked	into	is	how	well	the	different	models	are	suited	for	studying	NP‐cell	interactions.	
A	second	aspect,	for	instance,	is	the	possible	combination	of	several	of	these	models	is	a	very	
interesting	approach.	Using	co‐culture	models	or	flow	models	in	settings	that	are	suitable	for	
HCS,	would	enable	these	methods	to	be	used	as	rapid	screening	tools.	Additionally,	the	use	of	
3D	 models	 with	 dynamic	 flow	 or	 co‐cultures	 with	 dynamic	 flow	 would	 provide	 many	
opportunities	to	further	bridge	the	in	vitro‐in	vivo	gap	as	well	as	to	rapidly	study	the	targeting	
efficacy	of,	for	instance,	anti‐cancer	agent‐containing	NP	under	more	physiologically	relevant	
conditions.	The	use	of	3D	models	consisting	of	different	cell	types	would	also	open	up	many	
opportunities	and	could	serve	as	an	 important	 step	 towards	 the	development	of	artificial	
organs	for	NP	delivery/toxicity	screening.		
Given	the	rapid	developments	in	the	field	of	nanotoxicology	and	the	on‐going	maturation	of	
this	niche	area	into	a	full	scientific	discipline,	more	relevant	in	vitro	models	such	as	the	ones	
described	in	the	present	review	will	become	increasingly	important	in	various	research	areas	
that	are	linked	to	the	use	of	nanomaterials	 in	biological	settings.	Considering	that	most	of	
these	models	have	only	recently	been	introduced,	it	is	to	be	expected	that	more	optimized	
models	such	as	combinations	of	the	ones	mentioned	will	soon	be	set	up	and	will	have	big	
impacts	 on	our	understanding	of	 how	nanosized	materials	 interact	with	 cells	 and	 tissues	
under	physiologically	relevant	conditions.	
	
	
56	
	
	
	
	
	
	
References	
1.	 R.	A.	McIntyre,	Science	progress,	2012,	95,	1‐22.	
2.	 H.	Bouwmeester,	S.	Dekkers,	M.	Y.	Noordam,	W.	I.	Hagens,	A.	S.	Bulder,	C.	de	Heer,	S.	E.	
C.	G.	ten	Voorde,	S.	W.	P.	Wijnhoven,	H.	J.	P.	Marvin	and	A.	J.	A.	M.	Sips,	Regul	Toxicol	
Pharm,	2009,	53,	52‐62.	
3.	 T.	Thomas,	K.	Thomas,	N.	Sadrieh,	N.	Savage,	P.	Adair	and	R.	Bronaugh,	Toxicol	Sci,	
2006,	91,	14‐19.	
4.	 A.	M.	Schrand,	L.	Dai,	J.	J.	Schlager	and	S.	M.	Hussain,	Advances	in	experimental	medicine	
and	biology,	2012,	745,	58‐75.	
5.	 A.	D.	Maynard,	The	Annals	of	occupational	hygiene,	2007,	51,	1‐12.	
6.	 A.	D.	Maynard,	D.	B.	Warheit	and	M.	A.	Philbert,	Toxicol	Sci,	2011,	120	Suppl	1,	S109‐
129.	
7.	 C.	Som,	B.	Nowack,	H.	F.	Krug	and	P.	Wick,	Accounts	of	chemical	research,	2012.	
8.	 EU,	 ed.	 E.	 Commision,	 Official	 Journal	 of	 the	 European	 Union,	 Brussels,	 2011,	 vol.	
2011/696/EU.	
9.	 K.	Donaldson,	Nanomedicine	(Lond),	2006,	1,	229‐234.	
10.	 E.	M.	Vincent.	M.	Hoyt,	Journal	of	Chemical	Health	and	Safety,	2008,	15,	10‐15.	
11.	 S.	Arora,	J.	M.	Rajwade	and	K.	M.	Paknikar,	Toxicology	and	applied	pharmacology,	2012,	
258,	151‐165.	
12.	 L.	O.	Sillerud,	N.	O.	Solberg,	R.	Chamberlain,	R.	A.	Orlando,	J.	E.	Heidrich,	D.	C.	Brown,	
C.	I.	Brady,	T.	A.	Vander	Jagt,	M.	Garwood	and	D.	L.	Vander	Jagt,	Journal	of	Alzheimer's	
disease	:	JAD,	2012.	
13.	 Y.	Zhu,	P.	Chandra	and	Y.	B.	Shim,	Analytical	chemistry,	2012.	
14.	 L.	Liu,	Q.	Ye,	Y.	Wu,	W.	Y.	Hsieh,	C.	L.	Chen,	H.	H.	Shen,	S.	J.	Wang,	H.	Zhang,	T.	K.	Hitchens	
and	C.	Ho,	Nanomedicine	:	nanotechnology,	biology,	and	medicine,	2012,	8,	1345‐1354.	
15.	 D.	Ghosh,	Y.	Lee,	S.	Thomas,	A.	G.	Kohli,	D.	S.	Yun,	A.	M.	Belcher	and	K.	A.	Kelly,	Nature	
nanotechnology,	2012,	7,	677‐682.	
16.	 A.	Udhrain,	K.	M.	Skubitz	and	D.	W.	Northfelt,	International	journal	of	nanomedicine,	
2007,	2,	345‐352.	
17.	 S.	J.	Lee,	M.	S.	Huh,	S.	Y.	Lee,	S.	Min,	S.	Lee,	H.	Koo,	J.	U.	Chu,	K.	E.	Lee,	H.	Jeon,	Y.	Choi,	K.	
Choi,	Y.	Byun,	S.	Y.	Jeong,	K.	Park,	K.	Kim	and	I.	C.	Kwon,	Angew	Chem	Int	Ed	Engl,	2012,	
51,	7203‐7207.	
18.	 F.	Poltl‐Frank,	R.	Zurbriggen,	A.	Helg,	F.	Stuart,	J.	Robinson,	R.	Gluck	and	G.	Pluschke,	
Clinical	and	experimental	immunology,	1999,	117,	496‐503.	
19.	 D.	Meetoo,	Br	J	Nurs,	2009,	18,	1201‐1206.	
20.	 A.	El‐Ansary	and	S.	Al‐Daihan,	Journal	of	toxicology,	2009,	2009,	754810.	
21.	 R.	Duncan	and	R.	Gaspar,	Molecular	pharmaceutics,	2011,	8,	2101‐2141.	
57	
	
22.	 A.	Fernandez‐Fernandez,	R.	Manchanda	and	A.	J.	McGoron,	Applied	biochemistry	and	
biotechnology,	2011,	165,	1628‐1651.	
23.	 C.	Wang,	S.	Ravi,	G.	V.	Martinez,	V.	Chinnasamy,	P.	Raulji,	M.	Howell,	Y.	Davis,	J.	Mallela,	
M.	 S.	 Seehra	 and	 S.	Mohapatra,	 Journal	of	 controlled	 release	 :	official	 journal	of	 the	
Controlled	Release	Society,	2012,	163,	82‐92.	
24.	 D.	K.	Kirui,	I.	Khalidov,	Y.	Wang	and	C.	A.	Batt,	Nanomedicine	:	nanotechnology,	biology,	
and	medicine,	2012.	
25.	 Y.	X.	Wang,	S.	M.	Hussain	and	G.	P.	Krestin,	European	radiology,	2001,	11,	2319‐2331.	
26.	 D.	T.	Nguyen,	D.	J.	Kim	and	K.	S.	Kim,	Micron,	2011,	42,	207‐227.	
27.	 J.	Yang,	J.	Gunn,	S.	R.	Dave,	M.	Zhang,	Y.	A.	Wang	and	X.	Gao,	The	Analyst,	2008,	133,	
154‐160.	
28.	 A.	Nel,	T.	Xia,	L.	Madler	and	N.	Li,	Science,	2006,	311,	622‐627.	
29.	 S.	M.	Hussain,	L.	K.	Braydich‐Stolle,	A.	M.	Schrand,	R.	C.	Murdock,	K.	O.	Yu,	D.	M.	Mattie,	
J.	J.	Schlager	and	M.	Terrones,	Adv	Mater,	2009,	21,	1549‐1559.	
30.	 K.	Donaldson,	V.	Stone,	C.	L.	Tran,	W.	Kreyling	and	P.	J.	A.	Borm,	Occup	Environ	Med,	
2004,	61,	727‐728.	
31.	 H.	C.	Fischer	and	W.	C.	W.	Chan,	Current	opinion	in	biotechnology,	2007,	18,	565‐571.	
32.	 A.	Kroll,	M.	H.	Pillukat,	D.	Hahn	and	J.	Schnekenburger,	Archives	of	toxicology,	2012,	86,	
1123‐1136.	
33.	 N.	 A.	 Monteiro‐Riviere,	 A.	 O.	 Inman	 and	 L.	 W.	 Zhang,	 Toxicology	 and	 applied	
pharmacology,	2009,	234,	222‐235.	
34.	 Z.	 Magdolenova,	 Y.	 Lorenzo,	 A.	 Collins	 and	 M.	 Dusinska,	 Journal	 of	 toxicology	 and	
environmental	health.	Part	A,	2012,	75,	800‐806.	
35.	 E.	C.	Cho,	Q.	Zhang	and	Y.	Xia,	Nature	nanotechnology,	2011,	6,	385‐391.	
36.	 S.	K.	Mahto,	T.	H.	Yoon	and	S.	W.	Rhee,	Biomicrofluidics,	2010,	4.	
37.	 C.	Kirchner,	T.	Liedl,	S.	Kudera,	T.	Pellegrino,	A.	M.	Javier,	H.	E.	Gaub,	S.	Stolzle,	N.	Fertig	
and	W.	J.	Parak,	Nano	letters,	2005,	5,	331‐338.	
38.	 H.	J.	Johnston,	G.	Hutchison,	F.	M.	Christensen,	S.	Peters,	S.	Hankin	and	V.	Stone,	Crit	
Rev	Toxicol,	2010,	40,	328‐346.	
39.	 R.	Duffin,	L.	Tran,	D.	Brown,	V.	Stone	and	K.	Donaldson,	Inhal	Toxicol,	2007,	19,	849‐
856.	
40.	 S.	 J.	 Soenen,	 P.	 Rivera‐Gil,	 J.	 M.	 Montenegro,	 W.	 J.	 Parak,	 S.	 C.	 De	 Smedt	 and	 K.	
Braeckmans,	Nano	today,	2011,	6,	446‐465.	
41.	 Z.	E.	Allouni,	M.	R.	Cimpan,	P.	J.	Hol,	T.	Skodvin	and	N.	R.	Gjerdet,	Colloids	and	surfaces.	
B,	Biointerfaces,	2009,	68,	83‐87.	
42.	 C.	 M.	 Sayes	 and	 D.	 B.	 Warheit,	Wiley	 interdisciplinary	 reviews.	 Nanomedicine	 and	
nanobiotechnology,	2009,	1,	660‐670.	
43.	 S.	 George,	 S.	 Pokhrel,	 T.	 Xia,	 B.	 Gilbert,	 Z.	 Ji,	 M.	 Schowalter,	 A.	 Rosenauer,	 R.	
Damoiseaux,	K.	A.	Bradley,	L.	Madler	and	A.	E.	Nel,	ACS	nano,	2010,	4,	15‐29.	
44.	 A.	Nel,	T.	Xia,	L.	Madler	and	N.	Li,	Science,	2006,	311,	622‐627.	
45.	 G.	Oberdorster,	E.	Oberdorster	and	J.	Oberdorster,	Environmental	health	perspectives,	
2005,	113,	823‐839.	
46.	 E.	J.	Park	and	K.	Park,	Toxicol	Lett,	2009,	184,	18‐25.	
47.	 B.	 Chen,	 Y.	 Liu,	 W.	 M.	 Song,	 Y.	 Hayashi,	 X.	 C.	 Ding	 and	 W.	 H.	 Li,	 Biomedical	 and	
environmental	sciences	:	BES,	2011,	24,	593‐601.	
48.	 S.	J.	Soenen,	M.	De	Cuyper,	S.	C.	De	Smedt	and	K.	Braeckmans,	Methods	in	enzymology,	
2012,	509,	195‐224.	
58	
	
49.	 B.	Wang,	W.	Y.	Feng,	M.	T.	Zhu,	Y.	Wang,	M.	Wang,	Y.	Q.	Gu,	H.	Ouyang,	H.	J.	Wang,	M.	Li,	
Y.	L.	Zhao,	Z.	F.	Chai	and	H.	F.	Wang,	J	Nanopart	Res,	2009,	11,	41‐53.	
50.	 S.	 J.	 Soenen,	U.	Himmelreich,	N.	Nuytten	and	M.	De	Cuyper,	Biomaterials,	2011,	32,	
195‐205.	
51.	 J.	Niu,	A.	Azfer,	L.	M.	Rogers,	X.	Wang	and	P.	E.	Kolattukudy,	Cardiovascular	research,	
2007,	73,	549‐559.	
52.	 F.	 Pagliari,	 C.	Mandoli,	 G.	 Forte,	 E.	Magnani,	 S.	 Pagliari,	 G.	 Nardone,	 S.	 Licoccia,	M.	
Minieri,	P.	Di	Nardo	and	E.	Traversa,	ACS	nano,	2012,	6,	3767‐3775.	
53.	 L.	Gao,	J.	Zhuang,	L.	Nie,	J.	Zhang,	Y.	Zhang,	N.	Gu,	T.	Wang,	J.	Feng,	D.	Yang,	S.	Perrett	
and	X.	Yan,	Nature	nanotechnology,	2007,	2,	577‐583.	
54.	 D.	M.	Huang,	J.	K.	Hsiao,	Y.	C.	Chen,	L.	Y.	Chien,	M.	Yao,	Y.	K.	Chen,	B.	S.	Ko,	S.	C.	Hsu,	L.	
A.	Tai,	H.	Y.	Cheng,	S.	W.	Wang,	C.	S.	Yang	and	Y.	C.	Chen,	Biomaterials,	2009,	30,	3645‐
3651.	
55.	 F.	Marano,	S.	Hussain,	F.	Rodrigues‐Lima,	A.	Baeza‐Squiban	and	S.	Boland,	Archives	of	
toxicology,	2011,	85,	733‐741.	
56.	 N.	Singh,	B.	Manshian,	G.	 J.	 Jenkins,	S.	M.	Griffiths,	P.	M.	Williams,	T.	G.	Maffeis,	C.	 J.	
Wright	and	S.	H.	Doak,	Biomaterials,	2009,	30,	3891‐3914.	
57.	 T.	R.	Pisanic,	2nd,	J.	D.	Blackwell,	V.	I.	Shubayev,	R.	R.	Finones	and	S.	Jin,	Biomaterials,	
2007,	28,	2572‐2581.	
58.	 Y.	J.	Gu,	J.	P.	Cheng,	C.	C.	Lin,	Y.	W.	Lam,	S.	H.	Cheng	and	W.	T.	Wong,	Toxicology	and	
applied	pharmacology,	2009,	237,	196‐204.	
59.	 K.	Buyukhatipoglu	and	A.	M.	Clyne,	Journal	of	biomedical	materials	research.	Part	A,	
2011,	96,	186‐195.	
60.	 P.	Naumanen,	P.	Lappalainen	and	P.	Hotulainen,	Journal	of	microscopy,	2008,	231,	446‐
454.	
61.	 C.	W.	Gourlay	and	K.	R.	Ayscough,	Nature	reviews.	Molecular	cell	biology,	2005,	6,	583‐
589.	
62.	 V.	See,	P.	Free,	Y.	Cesbron,	P.	Nativo,	U.	Shaheen,	D.	J.	Rigden,	D.	G.	Spiller,	D.	G.	Fernig,	
M.	R.	White,	I.	A.	Prior,	M.	Brust,	B.	Lounis	and	R.	Levy,	ACS	nano,	2009,	3,	2461‐2468.	
63.	 S.	J.	Soenen,	J.	Demeester,	S.	C.	De	Smedt	and	K.	Braeckmans,	Biomaterials,	2012,	33,	
4882‐4888.	
64.	 S.	K.	Mahto,	C.	Park,	T.	H.	Yoon	and	S.	W.	Rhee,	Toxicol	in	Vitro,	2010,	24,	1070‐1077.	
65.	 T.	Cedervall,	I.	Lynch,	S.	Lindman,	T.	Berggard,	E.	Thulin,	H.	Nilsson,	K.	A.	Dawson	and	
S.	 Linse,	 Proceedings	 of	 the	 National	 Academy	 of	 Sciences	 of	 the	 United	 States	 of	
America,	2007,	104,	2050‐2055.	
66.	 G.	Maiorano,	 S.	 Sabella,	 B.	 Sorce,	 V.	 Brunetti,	M.	A.	Malvindi,	 R.	 Cingolani	 and	P.	 P.	
Pompa,	ACS	nano,	2010,	4,	7481‐7491.	
67.	 I.	Lynch,	A.	Salvati	and	K.	A.	Dawson,	Nature	nanotechnology,	2009,	4,	546‐547.	
68.	 M.	Mahmoudi,	S.	Laurent,	M.	A.	Shokrgozar	and	M.	Hosseinkhani,	ACS	nano,	2011,	5,	
7263‐7276.	
69.	 S.	Laurent,	C.	Burtea,	C.	Thirifays,	U.	O.	Hafeli	and	M.	Mahmoudi,	PloS	one,	2012,	7,	
e29997.	
70.	 M.	A.	Dobrovolskaia	and	S.	E.	McNeil,	Nature	nanotechnology,	2007,	2,	469‐478.	
71.	 J.	Curtis,	M.	Greenberg,	J.	Kester,	S.	Phillips	and	G.	Krieger,	Toxicological	reviews,	2006,	
25,	245‐260.	
72.	 U.	C.	Nygaard,	J.	S.	Hansen,	M.	Samuelsen,	T.	Alberg,	C.	D.	Marioara	and	M.	Lovik,	Toxicol	
Sci,	2009,	109,	113‐123.	
59	
	
73.	 K.	Donaldson,	P.	J.	Borm,	V.	Castranova	and	M.	Gulumian,	Particle	and	fibre	toxicology,	
2009,	6,	13.	
74.	 G.	Oberdorster,	A.	Maynard,	K.	Donaldson,	V.	Castranova,	J.	Fitzpatrick,	K.	Ausman,	J.	
Carter,	B.	Karn,	W.	Kreyling,	D.	Lai,	S.	Olin,	N.	Monteiro‐Riviere,	D.	Warheit	and	H.	Yang,	
Particle	and	fibre	toxicology,	2005,	2,	8.	
75.	 L.	Wu,	J.	Zhang	and	W.	Watanabe,	Advanced	drug	delivery	reviews,	2011,	63,	456‐469.	
76.	 J.	K.	Jiang,	G.	Oberdorster	and	P.	Biswas,	J	Nanopart	Res,	2009,	11,	77‐89.	
77.	 M.	Hassellov,	J.	W.	Readman,	J.	F.	Ranville	and	K.	Tiede,	Ecotoxicology,	2008,	17,	344‐
361.	
78.	 J.	M.	Hillegass,	A.	Shukla,	S.	A.	Lathrop,	M.	B.	MacPherson,	N.	K.	Fukagawa	and	B.	T.	
Mossman,	 Wiley	 interdisciplinary	 reviews.	 Nanomedicine	 and	 nanobiotechnology,	
2010,	2,	219‐231.	
79.	 C.	F.	Jones	and	D.	W.	Grainger,	Advanced	drug	delivery	reviews,	2009,	61,	438‐456.	
80.	 S.	 J.	 Kang,	 B.	 M.	 Kim,	 Y.	 J.	 Lee	 and	 H.	 W.	 Chung,	 Environmental	 and	 molecular	
mutagenesis,	2008,	49,	399‐405.	
81.	 W.	Lin,	Y.	W.	Huang,	X.	D.	Zhou	and	Y.	Ma,	Toxicology	and	applied	pharmacology,	2006,	
217,	252‐259.	
82.	 A.	Dhawan	and	V.	Sharma,	Analytical	and	bioanalytical	chemistry,	2010,	398,	589‐605.	
83.	 A.	Nel,	T.	Xia,	H.	Meng,	X.	Wang,	S.	Lin,	Z.	Ji	and	H.	Zhang,	Accounts	of	chemical	research,	
2012.	
84.	 D.	Y.	Lai,	Wiley	interdisciplinary	reviews.	Nanomedicine	and	nanobiotechnology,	2012,	
4,	1‐15.	
85.	 P.	Carol,	S.	Sreejith	and	A.	Ajayaghosh,	Chemistry,	an	Asian	journal,	2007,	2,	338‐348.	
86.	 Y.	Seto,	M.	Ochi,	S.	Onoue	and	S.	Yamada,	 Journal	of	pharmaceutical	and	biomedical	
analysis,	2010,	52,	781‐786.	
87.	 C.	Hanley,	A.	Thurber,	C.	Hanna,	A.	Punnoose,	J.	Zhang	and	D.	G.	Wingett,	Nanoscale	
research	letters,	2009,	4,	1409‐1420.	
88.	 B.	I.	Gerashchenko	and	R.	W.	Howell,	Cytometry.	Part	A	:	the	journal	of	the	International	
Society	for	Analytical	Cytology,	2003,	54,	1‐7.	
89.	 I.	Vermes,	C.	Haanen	and	C.	Reutelingsperger,	Journal	of	immunological	methods,	2000,	
243,	167‐190.	
90.	 V.	C.	Abraham,	D.	L.	Taylor	and	J.	R.	Haskins,	Trends	in	biotechnology,	2004,	22,	15‐22.	
91.	 X.	Zhou,	X.	Cao,	Z.	Perlman	and	S.	T.	Wong,	Journal	of	biomedical	informatics,	2006,	39,	
115‐125.	
92.	 T.	H.	Chung,	S.	H.	Wu,	M.	Yao,	C.	W.	Lu,	Y.	S.	Lin,	Y.	Hung,	C.	Y.	Mou,	Y.	C.	Chen	and	D.	M.	
Huang,	Biomaterials,	2007,	28,	2959‐2966.	
93.	 T.	 Hartung	 and	 E.	 Sabbioni,	 Wiley	 interdisciplinary	 reviews.	 Nanomedicine	 and	
nanobiotechnology,	2011.	
94.	 O.	 f.	 E.	 C.‐o.	 a.	 Development,	 Preliminary	 Review	 of	OECD	 Test	 Guidelines	 for	 their	
Applicability	to	Manufactured	Nanomaterials,	Organisation	for	Economic	Co‐operation	
and	Development,	2009.	
95.	 V.	Murashov,	P.	Schulte,	C.	Geraci	and	J.	Howard,	Industrial	health,	2011,	49,	280‐296.	
96.	 OECD,	in	In	Vitro	Skin	Irritation:	Reconstructed	Human	Epidermis	Test	Method,	2010,	
vol.	OECD	TG	439.	
97.	 OECD,	in	In	Vitro	Skin	Corrosion:	Reconstructed	Human	Epidermis	(RhE)	Test	Method,	
2004,	vol.	OECD	TG	431.	
98.	 OECD,	in	Acute	Eye	Irritation/Corrosion,	2002,	vol.	OECD	TG	405.	
60	
	
99.	 O.	o.	E.	C.‐o.	a.	Development,	in	Test	Guideline	451:		Carcinogenicity	Studies,	2008,	vol.	
OECD	TG	451.	
100.	 O.	 o.	 E.	 C.‐o.	 a.	 Development,	 in	 Test	 Guideline	 453:	 Combined	 Chronic	
Toxicity\Carcinogenicity	Studies,	2008,	vol.	OECD	TG	453.	
101.	 N.	Lewinski,	V.	Colvin	and	R.	Drezek,	Small,	2008,	4,	26‐49.	
102.	 V.	 Kumar,	 A.	 Kumari,	 P.	 Guleria	 and	 S.	 K.	 Yadav,	 Reviews	 of	 environmental	
contamination	and	toxicology,	2012,	215,	39‐121.	
103.	 M.	J.	Clift	and	V.	Stone,	Theranostics,	2012,	2,	668‐680.	
104.	 A.	 Kroll,	 M.	 H.	 Pillukat,	 D.	 Hahn	 and	 J.	 Schnekenburger,	 European	 journal	 of	
pharmaceutics	 and	 biopharmaceutics	 :	 official	 journal	 of	 Arbeitsgemeinschaft	 fur	
Pharmazeutische	Verfahrenstechnik	e.V,	2009,	72,	370‐377.	
105.	 P.	Rivera‐Gil,	D.	Jimenez	De	Aberasturi,	V.	Wulf,	B.	Pelaz,	P.	Del	Pino,	Y.	Zhao,	J.	M.	De	
La	 Fuente,	 I.	 Ruiz	 De	 Larramendi,	 T.	 Rojo,	 X.	 J.	 Liang	 and	W.	 J.	 Parak,	Accounts	 of	
chemical	research,	2012.	
106.	 T.	M.	Sager	and	V.	Castranova,	Particle	and	fibre	toxicology,	2009,	6.	
107.	 K.	Donaldson,	A.	 Schinwald,	F.	Murphy,	W.	S.	Cho,	R.	Duffin,	L.	Tran	and	C.	Poland,	
Accounts	of	chemical	research,	2012.	
108.	 K.	Wittmaack,	Environmental	health	perspectives,	2007,	115,	187‐194.	
109.	 C.	Monteiller,	L.	Tran,	W.	MacNee,	S.	Faux,	A.	Jones,	B.	Miller	and	K.	Donaldson,	Occup	
Environ	Med,	2007,	64,	609‐615.	
110.	 E.	K.	Rushton,	J.	Jiang,	S.	S.	Leonard,	S.	Eberly,	V.	Castranova,	P.	Biswas,	A.	Elder,	X.	Han,	
R.	Gelein,	 J.	Finkelstein	and	G.	Oberdorster,	 Journal	of	toxicology	and	environmental	
health.	Part	A,	2010,	73,	445‐461.	
111.	 G.	Oberdorster,	Journal	of	internal	medicine,	2010,	267,	89‐105.	
112.	 X.	 Han,	 N.	 Corson,	 P.	 Wade‐Mercer,	 R.	 Gelein,	 J.	 Jiang,	 M.	 Sahu,	 P.	 Biswas,	 J.	 N.	
Finkelstein,	A.	Elder	and	G.	Oberdorster,	Toxicology,	2012,	297,	1‐9.	
113.	 S.	H.	Doak,	B.	Manshian,	G.	J.	Jenkins	and	N.	Singh,	Mutation	research,	2012,	745,	104‐
111.	
114.	 Y.	Gavrieli,	Y.	Sherman	and	S.	A.	Ben‐Sasson,	The	 Journal	of	cell	biology,	1992,	119,	
493‐501.	
115.	 H.	F.	Krug	and	P.	Wick,	Angew	Chem	Int	Ed	Engl,	2011.	
116.	 J.	G.	Teeguarden,	P.	M.	Hinderliter,	G.	Orr,	B.	D.	Thrall	and	J.	G.	Pounds,	Toxicol	Sci,	2007,	
95,	300‐312.	
117.	 M.	Horie,	K.	Nishio,	K.	Fujita,	H.	Kato,	S.	Endoh,	M.	Suzuki,	A.	Nakamura,	A.	Miyauchi,	S.	
Kinugasa,	K.	Yamamoto,	H.	Iwahashi,	H.	Murayama,	E.	Niki	and	Y.	Yoshida,	Toxicol	in	
Vitro,	2010,	24,	1629‐1638.	
118.	 R.	 P.	 Bagwe,	 L.	 R.	 Hilliard	 and	W.	 Tan,	Langmuir	 :	 the	ACS	 journal	 of	 surfaces	and	
colloids,	2006,	22,	4357‐4362.	
119.	 P.	Bihari,	M.	Vippola,	S.	Schultes,	M.	Praetner,	A.	G.	Khandoga,	C.	A.	Reichel,	C.	Coester,	
T.	Tuomi,	M.	Rehberg	and	F.	Krombach,	Particle	and	fibre	toxicology,	2008,	5,	14.	
120.	 Y.	P.	Sun,	X.	Q.	Li,	W.	X.	Zhang	and	H.	P.	Wang,	Colloid	Surface	A,	2007,	308,	60‐66.	
121.	 S.	Q.	Zhu,	E.	Oberdorster	and	M.	L.	Haasch,	Mar	Environ	Res,	2006,	62,	S5‐S9.	
122.	 D.	Porter,	K.	Sriram,	M.	Wolfarth,	A.	Jefferson,	D.	Schwegler‐Berry,	M.	Andrew	and	V.	
Castranova,	Nanotoxicology,	2008,	2,	144‐154.	
123.	 S.	T.	Stern	and	S.	E.	McNeil,	Toxicol	Sci,	2008,	101,	4‐21.	
124.	 X.	Han,	R.	Gelein,	N.	Corson,	P.	Wade‐Mercer,	 J.	 Jiang,	P.	Biswas,	 J.	N.	Finkelstein,	A.	
Elder	and	G.	Oberdorster,	Toxicology,	2011,	287,	99‐104.	
61	
	
125.	 S.	M.	Griffiths,	N.	Singh,	G.	J.	Jenkins,	P.	M.	Williams,	A.	W.	Orbaek,	A.	R.	Barron,	C.	J.	
Wright	and	S.	H.	Doak,	Analytical	chemistry,	2011,	83,	3778‐3785.	
126.	 S.	J.	Soenen	and	M.	De	Cuyper,	Nanomedicine	(Lond),	2010,	5,	1261‐1275.	
127.	 S.	 J.	 Soenen,	 B.	 Manshian,	 J.	 M.	 Montenegro,	 F.	 Amin,	 B.	 Meermann,	 T.	 Thiron,	 M.	
Cornelissen,	F.	Vanhaecke,	S.	Doak,	W.	J.	Parak,	S.	De	Smedt	and	K.	Braeckmans,	ACS	
nano,	2012,	6,	5767‐5783.	
128.	 R.	Damoiseaux,	S.	George,	M.	Li,	S.	Pokhrel,	Z.	Ji,	B.	France,	T.	Xia,	E.	Suarez,	R.	Rallo,	L.	
Madler,	Y.	Cohen,	E.	M.	Hoek	and	A.	Nel,	Nanoscale,	2011,	3,	1345‐1360.	
129.	 S.	Bakand,	A.	Hayes	and	F.	Dechsakulthorn,	Inhal	Toxicol,	2012,	24,	125‐135.	
130.	 S.	 C.	 Kim,	 D.	 R.	 Chen,	 C.	 Qi,	 R.	 M.	 Gelein,	 J.	 N.	 Finkelstein,	 A.	 Elder,	 K.	 Bentley,	 G.	
Oberdorster	and	D.	Y.	Pui,	Nanotoxicology,	2010,	4,	42‐51.	
131.	 P.	M.	Hinderliter,	K.	R.	Minard,	G.	Orr,	W.	B.	Chrisler,	B.	D.	Thrall,	J.	G.	Pounds	and	J.	G.	
Teeguarden,	Particle	and	fibre	toxicology,	2010,	7,	36.	
132.	 D.	Lison,	L.	C.	Thomassen,	V.	Rabolli,	L.	Gonzalez,	D.	Napierska,	J.	W.	Seo,	M.	Kirsch‐
Volders,	P.	Hoet,	C.	E.	Kirschhock	and	J.	A.	Martens,	Toxicol	Sci,	2008,	104,	155‐162.	
133.	 A.	Astashkina,	B.	Mann	and	D.	W.	Grainger,	Pharmacology	&	therapeutics,	2012,	134,	
82‐106.	
134.	 Y.	Cohen,	R.	Rallo,	R.	Liu	and	H.	H.	Liu,	Accounts	of	chemical	research,	2012.	
135.	 L.	K.	Schnackenberg,	J.	Sun	and	R.	D.	Beger,	Methods	Mol	Biol,	2012,	926,	141‐156.	
136.	 P.	J.	O'Brien,	W.	Irwin,	D.	Diaz,	E.	Howard‐Cofield,	C.	M.	Krejsa,	M.	R.	Slaughter,	B.	Gao,	
N.	Kaludercic,	A.	Angeline,	P.	Bernardi,	P.	Brain	and	C.	Hougham,	Archives	of	toxicology,	
2006,	80,	580‐604.	
137.	 E.	Jan,	S.	J.	Byrne,	M.	Cuddihy,	A.	M.	Davies,	Y.	Volkov,	Y.	K.	Gun'ko	and	N.	A.	Kotov,	ACS	
nano,	2008,	2,	928‐938.	
138.	 T.	Puzyn,	B.	Rasulev,	A.	Gajewicz,	X.	K.	Hu,	T.	P.	Dasari,	A.	Michalkova,	H.	M.	Hwang,	A.	
Toropov,	D.	Leszczynska	and	J.	Leszczynski,	Nature	nanotechnology,	2011,	6,	175‐178.	
139.	 A.	J.	Hill,	H.	Teraoka,	W.	Heideman	and	R.	E.	Peterson,	Toxicol	Sci,	2005,	86,	6‐19.	
140.	 C.	Y.	Usenko,	S.	L.	Harper	and	R.	L.	Tanguay,	Carbon,	2007,	45,	1891‐1898.	
141.	 O.	Bar‐Ilan,	R.	M.	Albrecht,	V.	E.	Fako	and	D.	Y.	Furgeson,	Small,	2009,	5,	1897‐1910.	
142.	 T.	C.	King‐Heiden,	P.	N.	Wiecinski,	A.	N.	Mangham,	K.	M.	Metz,	D.	Nesbit,	J.	A.	Pedersen,	
R.	 J.	Hamers,	W.	Heideman	and	R.	E.	Peterson,	Environmental	science	&	 technology,	
2009,	43,	1605‐1611.	
143.	 S.	 George,	 T.	 Xia,	 R.	 Rallo,	 Y.	 Zhao,	 Z.	 Ji,	 S.	 Lin,	 X.	 Wang,	 H.	 Zhang,	 B.	 France,	 D.	
Schoenfeld,	R.	Damoiseaux,	R.	Liu,	S.	Lin,	K.	A.	Bradley,	Y.	Cohen	and	A.	E.	Nel,	ACS	nano,	
2011,	5,	1805‐1817.	
144.	 J.	Wang,	X.	Fang	and	W.	Liang,	ACS	nano,	2012,	6,	5018‐5030.	
145.	 C.	Albrecht,	A.	M.	Scherbart,	D.	van	Berlo,	C.	M.	Braunbarth,	R.	P.	Schins	and	J.	Scheel,	
Toxicol	in	Vitro,	2009,	23,	520‐530.	
146.	 L.	Bregoli,	F.	Chiarini,	A.	Gambarelli,	G.	Sighinolfi,	A.	M.	Gatti,	P.	Santi,	A.	M.	Martelli	and	
L.	Cocco,	Toxicology,	2009,	262,	121‐129.	
147.	 A.	Lankoff,	W.	J.	Sandberg,	A.	Wegierek‐Ciuk,	H.	Lisowska,	M.	Refsnes,	B.	Sartowska,	P.	
E.	Schwarze,	S.	Meczynska‐Wielgosz,	M.	Wojewodzka	and	M.	Kruszewski,	Toxicol	Lett,	
2012,	208,	197‐213.	
148.	 F.	Zhao,	Y.	Zhao,	Y.	Liu,	X.	L.	Chang,	C.	Y.	Chen	and	Y.	L.	Zhao,	Small,	2011,	7,	1322‐1337.	
149.	 T.	T.	Wang,	J.	Bai,	X.	Jiang	and	G.	U.	Nienhaus,	ACS	nano,	2012,	6,	1251‐1259.	
150.	 C.	 Schweiger,	 R.	 Hartmann,	 F.	 Zhang,	 W.	 J.	 Parak,	 T.	 H.	 Kissel	 and	 P.	 Rivera	 Gil,	 J	
Nanobiotechnol,	2012,	10.	
62	
	
151.	 I.	 Sur,	 D.	 Cam,	 M.	 Kahraman,	 A.	 Baysal	 and	 M.	 Culha,	 Nanotechnology,	 2010,	 21,	
175104.	
152.	 J.	A.	Coulter,	S.	Jain,	K.	T.	Butterworth,	L.	E.	Taggart,	G.	R.	Dickson,	S.	J.	McMahon,	W.	B.	
Hyland,	M.	F.	Muir,	C.	Trainor,	A.	R.	Hounsell,	J.	M.	O'Sullivan,	G.	Schettino,	F.	J.	Currell,	
D.	G.	Hirst	and	K.	M.	Prise,	International	journal	of	nanomedicine,	2012,	7,	2673‐2685.	
153.	 O.	 Lunov,	 T.	 Syrovets,	 C.	 Loos,	 J.	 Beil,	 M.	 Delecher,	 K.	 Tron,	 G.	 U.	 Nienhaus,	 A.	
Musyanovych,	V.	Mailander,	K.	Landfester	and	T.	Simmet,	ACS	nano,	2011,	5,	1657‐
1669.	
154.	 B.	Diaz,	C.	Sanchez‐Espinel,	M.	Arruebo,	J.	Faro,	E.	de	Miguel,	S.	Magadan,	C.	Yague,	R.	
Fernandez‐Pacheco,	 M.	 R.	 Ibarra,	 J.	 Santamaria	 and	 A.	 Gonzalez‐Fernandez,	 Small,	
2008,	4,	2025‐2034.	
155.	 C.	Greulich,	J.	Diendorf,	J.	Gessmann,	T.	Simon,	T.	Habijan,	G.	Eggeler,	T.	A.	Schildhauer,	
M.	Epple	and	M.	Koller,	Acta	biomaterialia,	2011,	7,	3505‐3514.	
156.	 S.	Barua	and	K.	Rege,	Small,	2009,	5,	370‐376.	
157.	 S.	M.	 Chowdhury,	 G.	 Lalwani,	 K.	 V.	 Zhang,	 J.	 Y.	 Yang,	 K.	Neville	 and	B.	 Sitharaman,	
Biomaterials,	2013,	34,	283‐293.	
158.	 T.	Xia,	M.	Kovochich,	M.	Liong,	J.	I.	Zink	and	A.	E.	Nel,	ACS	nano,	2008,	2,	85‐96.	
159.	 Y.	Wang,	W.	G.	Aker,	H.	M.	Hwang,	C.	G.	Yedjou,	H.	Yu	and	P.	B.	Tchounwou,	The	Science	
of	the	total	environment,	2011,	409,	4753‐4762.	
160.	 H.	Wang,	D.	Wingett,	M.	H.	 Engelhard,	K.	 Feris,	K.	M.	Reddy,	 P.	 Turner,	 J.	 Layne,	 C.	
Hanley,	 J.	 Bell,	 D.	 Tenne,	 C.	 Wang	 and	 A.	 Punnoose,	 Journal	 of	materials	 science.	
Materials	in	medicine,	2009,	20,	11‐22.	
161.	 C.	Hanley,	J.	Layne,	A.	Punnoose,	K.	M.	Reddy,	I.	Coombs,	A.	Coombs,	K.	Feris	and	D.	
Wingett,	Nanotechnology,	2008,	19,	295103.	
162.	 S.	K.	Sohaebuddin,	P.	T.	Thevenot,	D.	Baker,	J.	W.	Eaton	and	L.	P.	Tang,	Particle	and	fibre	
toxicology,	2010,	7.	
163.	 J.	S.	Chang,	K.	L.	Chang,	D.	F.	Hwang	and	Z.	L.	Kong,	Environmental	science	&	technology,	
2007,	41,	2064‐2068.	
164.	 J.	A.	Kim,	C.	Aberg,	A.	Salvati	and	K.	A.	Dawson,	Nature	nanotechnology,	2012,	7,	62‐68.	
165.	 S.	G.	Mukherjee,	N.	O'Claonadh,	A.	Casey	and	G.	Chambers,	Toxicol	in	Vitro,	2012,	26,	
238‐251.	
166.	 H.	Zhang,	T.	Xia,	H.	Meng,	M.	Xue,	S.	George,	Z.	Ji,	X.	Wang,	R.	Liu,	M.	Wang,	B.	France,	R.	
Rallo,	R.	Damoiseaux,	Y.	Cohen,	K.	A.	Bradley,	J.	I.	Zink	and	A.	E.	Nel,	ACS	nano,	2011,	5,	
2756‐2769.	
167.	 A.	Haase,	S.	Rott,	A.	Mantion,	P.	Graf,	J.	Plendl,	A.	F.	Thunemann,	W.	P.	Meier,	A.	Taubert,	
A.	Luch	and	G.	Reiser,	Toxicol	Sci,	2012,	126,	457‐468.	
168.	 G.	Saretzki,	L.	Armstrong,	A.	Leake,	M.	Lako	and	T.	von	Zglinicki,	Stem	Cells,	2004,	22,	
962‐971.	
169.	 M.	Vippola,	G.	C.	Falck,	H.	K.	Lindberg,	S.	Suhonen,	E.	Vanhala,	H.	Norppa,	K.	Savolainen,	
A.	Tossavainen	and	T.	Tuomi,	Human	&	experimental	toxicology,	2009,	28,	377‐385.	
170.	 I.	Gosens,	J.	A.	Post,	L.	J.	J.	de	la	Fonteyne,	E.	H.	J.	M.	Jansen,	J.	W.	Geus,	F.	R.	Cassee	and	
W.	H.	de	Jong,	Particle	and	fibre	toxicology,	2010,	7.	
171.	 A.	Albanese	and	W.	C.	W.	Chan,	ACS	nano,	2011,	5,	5478‐5489.	
172.	 S.	C.	Brown,	M.	Kamal,	N.	Nasreen,	A.	Baumuratov,	P.	Sharma,	V.	B.	Antony	and	B.	M.	
Moudgil,	Adv	Powder	Technol,	2007,	18,	69‐79.	
173.	 L.	K.	Limbach,	Y.	C.	Li,	R.	N.	Grass,	T.	J.	Brunner,	M.	A.	Hintermann,	M.	Muller,	D.	Gunther	
and	W.	J.	Stark,	Environmental	science	&	technology,	2005,	39,	9370‐9376.	
174.	 L.	V.	Stebounova,	E.	Guio	and	V.	H.	Grassian,	J	Nanopart	Res,	2011,	13,	233‐244.	
63	
	
175.	 D.	 Drescher,	 G.	 Orts‐Gil,	 G.	 Laube,	 K.	 Natte,	 R.	 W.	 Veh,	 W.	 Osterle	 and	 J.	 Kneipp,	
Analytical	and	bioanalytical	chemistry,	2011,	400,	1367‐1373.	
176.	 R.	C.	Murdock,	L.	Braydich‐Stolle,	A.	M.	Schrand,	J.	J.	Schlager	and	S.	M.	Hussain,	Toxicol	
Sci,	2008,	101,	239‐253.	
177.	 K.	Braeckmans,	K.	Buyens,	W.	Bouquet,	C.	Vervaet,	P.	Joye,	F.	De	Vos,	L.	Plawinski,	L.	
Doeuvre,	E.	Angles‐Cano,	N.	N.	Sanders,	J.	Demeester	and	S.	C.	De	Smedt,	Nano	letters,	
2010,	10,	4435‐4442.	
178.	 P.	Wick,	P.	Manser,	L.	K.	Limbach,	U.	Dettlaff‐Weglikowska,	F.	Krumeich,	S.	Roth,	W.	J.	
Stark	and	A.	Bruinink,	Toxicol	Lett,	2007,	168,	121‐131.	
179.	 J.	M.	Zook,	R.	I.	MacCuspie,	L.	E.	Locascio,	M.	D.	Halter	and	J.	T.	Elliott,	Nanotoxicology,	
2011,	5,	517‐530.	
180.	 E.	 Bae,	 H.	 J.	 Park,	 J.	 Lee,	 Y.	 Kim,	 J.	 Yoon,	 K.	 Park,	 K.	 Choi	 and	 J.	 Yi,	Environmental	
toxicology	and	chemistry	/	SETAC,	2010,	29,	2154‐2160.	
181.	 D.	Yoon,	D.	Woo,	J.	H.	Kim,	M.	K.	Kim,	T.	Kim,	E.	S.	Hwang	and	S.	Baik,	J	Nanopart	Res,	
2011,	13,	2543‐2551.	
182.	 D.	Kim,	Y.	S.	Lin	and	C.	L.	Haynes,	Analytical	chemistry,	2011,	83,	8377‐8382.	
183.	 J.	Ando	and	K.	Yamamoto,	Antioxidants	&	redox	signaling,	2011,	15,	1389‐1403.	
184.	 T.	 Bhowmick,	 E.	 Berk,	 X.	 Cui,	 V.	 R.	 Muzykantov	 and	 S.	Muro,	 Journal	 of	 controlled	
release	:	official	journal	of	the	Controlled	Release	Society,	2012,	157,	485‐492.	
185.	 S.	P.	Samuel,	N.	Jain,	F.	O'Dowd,	T.	Paul,	D.	Kashanin,	V.	A.	Gerard,	Y.	K.	Gun'ko,	A.	Prina‐
Mello	and	Y.	Volkov,	International	journal	of	nanomedicine,	2012,	7,	2943‐2956.	
186.	 A.	Lin,	A.	Sabnis,	S.	Kona,	S.	Nattama,	H.	Patel,	J.	F.	Dong	and	K.	T.	Nguyen,	Journal	of	
Biomedical	Materials	Research	Part	A,	2010,	93A,	833‐842.	
187.	 O.	 C.	 Farokhzad,	 A.	 Khademhosseini,	 S.	 Y.	 Yon,	 A.	 Hermann,	 J.	 J.	 Cheng,	 C.	 Chin,	 A.	
Kiselyuk,	B.	Teply,	G.	Eng	and	R.	Langer,	Analytical	chemistry,	2005,	77,	5453‐5459.	
188.	 J.	Kusunose,	H.	Zhang,	M.	K.	Gagnon,	T.	Pan,	S.	I.	Simon	and	K.	W.	Ferrara,	Ann	Biomed	
Eng,	2013,	41,	89‐99.	
189.	 R.	E.	Unger,	S.	Halstenberg,	A.	Sartoris	and	C.	J.	Kirkpatrick,	Methods	Mol	Biol,	2011,	
695,	229‐241.	
190.	 K.	Savolainen,	H.	Alenius,	H.	Norppa,	L.	Pylkkanen,	T.	Tuomi	and	G.	Kasper,	Toxicology,	
2010,	269,	92‐104.	
191.	 C.	M.	Sayes,	K.	L.	Reed,	S.	Subramoney,	L.	Abrams	and	D.	B.	Warheit,	J	Nanopart	Res,	
2009,	11,	421‐431.	
192.	 J.	Kasper,	M.	I.	Hermanns,	C.	Bantz,	S.	Utech,	O.	Koshkina,	M.	Maskos,	C.	Brochhausen,	
C.	 Pohl,	 S.	 Fuchs,	 R.	 E.	 Unger	 and	 C.	 James	 Kirkpatrick,	 European	 journal	 of	
pharmaceutics	 and	 biopharmaceutics	 :	 official	 journal	 of	 Arbeitsgemeinschaft	 fur	
Pharmazeutische	Verfahrenstechnik	e.V,	2012.	
193.	 J.	Kasper,	M.	I.	Hermanns,	C.	Bantz,	M.	Maskos,	R.	Stauber,	C.	Pohl,	R.	E.	Unger	and	J.	C.	
Kirkpatrick,	Particle	and	fibre	toxicology,	2011,	8.	
194.	 B.	Rothen‐Rutishauser,	C.	Muhlfeld,	F.	Blank,	C.	Musso	and	P.	Gehr,	Particle	and	fibre	
toxicology,	2007,	4,	9.	
195.	 J.	Pinkernelle,	P.	Calatayud,	G.	F.	Goya,	H.	Fansa	and	G.	Keilhoff,	Bmc	Neurosci,	2012,	
13.	
196.	 R.	 Wottrich,	 S.	 Diabate	 and	 H.	 F.	 Krug,	 International	 journal	 of	 hygiene	 and	
environmental	health,	2004,	207,	353‐361.	
197.	 H.	Ishii,	S.	Hayashi,	J.	C.	Hogg,	T.	Fujii,	Y.	Goto,	N.	Sakamoto,	H.	Mukae,	R.	Vincent	and	
S.	F.	van	Eeden,	Resp	Res,	2005,	6.	
64	
	
198.	 K.	H.	Kim,	S.	Y.	Kim,	B.	H.	Chun,	Y.	K.	Lee	and	N.	Chung,	J	Korean	Soc	Appl	Bi,	2011,	54,	
30‐36.	
199.	 B.	R.;,	M.	P.;,	C.	M.;	and	G.	M.,	BioMed	Research	International,	2013,	2013,	8.	
200.	 M.	D.	Ramos‐Godinez,	B.	E.	Gonzalez‐Gomez,	A.	Montiel‐Davalos,	R.	Lopez‐Marure	and	
E.	Alfaro‐Moreno,	Toxicol	in	Vitro,	2012,	27,	774‐781.	
201.	 C.	E.	 Soma,	C.	Dubernet,	G.	Barratt,	 S.	Benita	and	P.	Couvreur,	 Journal	of	Controlled	
Release,	2000,	68,	283‐289.	
202.	 K.	M.	Al‐Hallak,	S.	Azarmi,	A.	Anwar‐Mohamed,	W.	H.	Roa	and	R.	Lobenberg,	European	
journal	of	pharmaceutics	and	biopharmaceutics	:	official	journal	of	Arbeitsgemeinschaft	
fur	Pharmazeutische	Verfahrenstechnik	e.V,	2010,	76,	112‐119.	
203.	 D.	van	Berlo,	A.	Wessels,	A.	W.	Boots,	V.	Wilhelmi,	A.	M.	Scherbart,	K.	Gerloff,	F.	J.	van	
Schooten,	C.	Albrecht	and	R.	P.	Schins,	Free	radical	biology	&	medicine,	2010,	49,	1685‐
1693.	
204.	 E.	Alfaro‐Moreno,	T.	S.	Nawrot,	B.	M.	Vanaudenaerde,	M.	F.	Hoylaerts,	J.	A.	Vanoirbeek,	
B.	Nemery	and	P.	H.	Hoet,	The	European	 respiratory	 journal	 :	official	 journal	of	 the	
European	Society	for	Clinical	Respiratory	Physiology,	2008,	32,	1184‐1194.	
205.	 L.	Muller,	M.	Riediker,	P.	Wick,	M.	Mohr,	P.	Gehr	and	B.	Rothen‐Rutishauser,	Journal	of	
the	Royal	Society,	Interface	/	the	Royal	Society,	2010,	7	Suppl	1,	S27‐40.	
206.	 D.	Huh,	G.	A.	Hamilton	and	D.	E.	Ingber,	Trends	Cell	Biol,	2011,	21,	745‐754.	
207.	 T.	T.	Goodman,	C.	P.	Ng	and	S.	H.	Pun,	Bioconjugate	chemistry,	2008,	19,	1951‐1959.	
208.	 Y.	Luo,	C.	Wang,	M.	Hossain,	Y.	Qiao,	L.	Ma,	J.	An	and	M.	Su,	Analytical	chemistry,	2012,	
84,	6731‐6738.	
209.	 C.	Godugu,	A.	R.	Patel,	U.	Desai,	T.	Andey,	A.	Sams	and	M.	Singh,	PloS	one,	 2013,	8,	
e53708.	
210.	 C.	T.	Kuo,	C.	L.	Chiang,	R.	Y.	J.	Huang,	H.	Lee	and	A.	M.	Wo,	Npg	Asia	Mater,	2012,	4.	
211.	 A.	Nyga,	U.	Cheema	and	M.	Loizidou,	Journal	of	cell	communication	and	signaling,	2011,	
5,	239‐248.	
212.	 M.	Mitra,	C.	Mohanty,	A.	Harilal,	U.	K.	Maheswari,	S.	K.	Sahoo	and	S.	Krishnakumar,	
Molecular	vision,	2012,	18,	1361‐1378.	
213.	 M.	 Biondi,	 D.	 Guarnieri,	 H.	 Yu,	 V.	 Belli	 and	 P.	 A.	 Netti,	Nanotechnology,	 2013,	 24,	
045101.	
214.	 K.	Huang,	H.	Ma,	J.	Liu,	S.	Huo,	A.	Kumar,	T.	Wei,	X.	Zhang,	S.	Jin,	Y.	Gan,	P.	C.	Wang,	S.	
He,	X.	Zhang	and	X.	J.	Liang,	ACS	nano,	2012,	6,	4483‐4493.	
215.	 J.	Lee,	G.	D.	Lilly,	R.	C.	Doty,	P.	Podsiadlo	and	N.	A.	Kotov,	Small,	2009,	5,	1213‐1221.	
216.	 D.	Movia,	A.	Prina‐Mello,	D.	Bazou,	Y.	Volkov	and	S.	Giordani,	ACS	nano,	2011,	5,	9278‐
9290.	
217.	 M.	Yu,	S.	H.	Huang,	K.	J.	Yu	and	A.	M.	Clyne,	Int	J	Mol	Sci,	2012,	13,	5554‐5570.	
218.	 S.	Hackenberg,	F.	Z.	Zimmermann,	A.	Scherzed,	G.	Friehs,	K.	Froelich,	C.	Ginzkey,	C.	
Koehler,	 M.	 Burghartz,	 R.	 Hagen	 and	 N.	 Kleinsasser,	 Environmental	 and	molecular	
mutagenesis,	2011,	52,	582‐589.	
	
	
